

Rochelle Paula Walensky, MD, MPH
Curriculum Vitae

Education

09/1987-	A.B.	Biochemistry & Molecular	Washington University in
05/1991	<i>Summa Cum Laude</i>	Biology	St. Louis
09/1991-	M.D.		Johns Hopkins University
05/1995			School of Medicine
07/1999-	MPH	Clinical Effectiveness	Harvard School of Public
05/2001			Health

Postdoctoral Training

07/1995-	Osler Medical House	Internal Medicine Residency	The Johns Hopkins Hospital
06/1998	Staff, Longcope Firm	Training Program	
07/1998-	Clinical Fellow	Infectious Disease Training	Brigham & Women's
06/1999		Program	Hospital/Massachusetts
			General Hospital
07/1999-	Research Fellow	Infectious Disease Training	Brigham & Women's
06/2001		Program	Hospital/Massachusetts
			General Hospital
2014-2016	Faculty participant	Physician's Leadership	Massachusetts General
		Development Course	Physician's Organization
			(MGPO)

Faculty Academic Appointments

07/1998-	Research Fellow	Medicine	Harvard University
06/2001			
07/2001-	Instructor	Medicine	Harvard Medical School
12/2003			
01/2004-	Assistant Professor	Medicine	Harvard Medical School
08/2007			
09/2007-	Associate Professor	Medicine	Harvard Medical School
11/2012			
12/2012-	Professor	Medicine	Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

Past

07/1998-	Clinical/Research	Medicine	Brigham and Women's
06/2001	Fellow		Hospital
07/2000-	Clinical/Research	Medicine	Massachusetts General
08/2001	Fellow		Hospital
07/2000-	Graduate Assistant	Medical Walk-in Unit	Massachusetts General
07/2001			Hospital
07/2001-	Associate Physician	Medicine/Infectious Disease	Brigham and Women's
01/2021		Service	Hospital

07/2001- 01/2021	Attending Physician	Infectious Disease Service (inpatient)	Massachusetts General Hospital and Brigham and Women's Hospital
08/2001- 04/2005	Assistant in Medicine	Infectious Disease Unit	Massachusetts General Hospital
04/2005- 04/2009	Assistant Physician	Medicine/Infectious Disease Unit	Massachusetts General Hospital
04/2009- 04/2013	Associate Physician	Medicine/Infectious Disease Unit	Massachusetts General Hospital
09/2017- 01/2021	Chief	Division of Infectious Diseases	Massachusetts General Hospital

Other Professional Positions

2011	HIV Executive Committee	Massachusetts General Hospital
2021-	Director and Administrator	Centers for Disease Control and Prevention and the Administrator of the Agency for Toxic Substances and Disease Registry

Major Administrative Leadership Positions

Local

2001-2010	Director/Facilitator	HIV Clinical Research Conference, Harvard Center for AIDS Research (CFAR)
2005-2011	Associate Director	Program in Epidemiology and Outcomes, CFAR
2011-2017	Director, Program in Epidemiology and Outcomes Research in Infectious Diseases	Massachusetts General Hospital
2011-2020	Co-Director, Medical Practice Evaluation Center	Massachusetts General Hospital
2019-2021	Member, Board of Directors	Partners Healthcare

National and International

2010-2013	HIVMA Representative	Infectious Disease Society of America Annual Meeting Program Committee
2012	International AIDS Conference, Washington DC Scientific Program Committee	International AIDS Society Track E, Co-chair
2015-2018	HIVMA Board Member	Infectious Disease Society of America
2019-2021	HIVMA Vice Chair	Infectious Disease Society of America

Committee Service

Local

2004- 2021	Joint Committee on the Status of Women	Harvard Medical School
	2005-2008	Maternity Leave subcommittee co-Chair

2009-2010	Task Force on Faculty Development and Diversity	Harvard Medical School
2009-2010	Conflict of Interest, Faculty Reaction Group Committee	Harvard Medical School
2011-2021	Task Force on Faculty Development & Diversity, Dean's Advisory Committee on Implementation	Harvard Medical School
2011-2021	Standing Committee on the Conflicts of Interest and Commitment	Harvard Medical School
2011-2021	Office of Women's Careers, Women in Academic Medicine Advisory Council	Massachusetts General Hospital
2020-2021	Governor Charles Baker, COVID-19 Advisory Group	MA State Government
2020-2021	Governor Charles Baker, Reopening Advisory Board for COVID-19	MA State Government
2021-2021	Worcester Polytechnic Institute (WPI), Medical Advisory Board	Worcester Polytechnic Institute (WPI)

National and International

2009	Antiretroviral Treatment Guidelines	World Health Organization Consultant
2009	Consultancy to the Obama National HIV/AIDS Strategy	HIV Medical Association
2010	Social and Behavioral HIV Prevention Think Tank Meeting	NIH, Office of AIDS Research Participant
2010	Strategic Planning to Develop the Natural History and Epidemiology Component of the <i>Trans-NIH Plan for HIV-Related Research</i>	Office of AIDS Research, National Institutes of Health
2011	International AIDS Society	2012 Organizational Committee Track E (Implementation Science, Health Systems and Economics) - Co-Chair
2011-14	Office of AIDS Research Advisory Council	Office of AIDS Research, National Institutes of Health, Member
2014-15	Office of AIDS Research Advisory Council	Office of AIDS Research, National Institutes of Health, Chair
2011-2020	DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents	Office of AIDS Research, National Institutes of Health
2015-2021	Doris Duke Charitable Foundation	Scientific Advisory Board
2015-2021	Scientific and Technical Advisory Committee (STAC)	UNAIDS

Professional Societies

2000-	Massachusetts Infectious Disease Society	Member
2000-2009	Infectious Disease Society of America	Member

2000-	Society for Medical Decision Making	Member
2006-	Infectious Disease Society of America	Fellow
2010-	American College of Physicians	Fellow
2011-	American Society of Clinical Investigation	Member
2015-	American Academy of Physicians	Member
2021-	National Academy of Medicine	Member

Grant Review Activities

2006	Special Emphasis Panel	National Institutes of Health
	Scientific Review Group 2006/10 ZRG1	Member
	Scientific Review Group 2007/01 ZRG1	Member
2008	ECOR – Claflin Awards	Massachusetts General Hospital
		Ad hoc reviewer
2009	Special Emphasis Panel	National Institutes of Health
	ARRA Challenge Grant Review	Member
2009-2021	Center for AIDS Research Developmental Awards	Harvard Medical School
		Ad hoc reviewer
2009	African Health Initiative (\$8-\$15M)	Doris Duke Charitable Foundation
		Reviewer
2015, 2018	Clinical Scientist Development Award	Doris Duke Charitable Foundation
		Chair of Review Panel
2015	Fund to Retain Clinical Scientist Award	Doris Duke Charitable Foundation
		Reviewer

Editorial Activities

Journal of Acquired Immune Deficiency Syndromes – reviewer
Medical Decision Making – reviewer
Value in Health – reviewer
Medical Care – reviewer
Clinical Infectious Diseases – reviewer
Journal of Infectious Diseases – reviewer
Journal of American Medical Association – reviewer
AIDS – reviewer
The Lancet – reviewer
The New England Journal of Medicine – reviewer
Annals of Internal Medicine – reviewer
PLoS Medicine – reviewer
Medscape HIV/AIDS – reviewer

Other Editorial Roles

2010-2021	Advisory Board	Medscape HIV/AIDS
2020-2021	Medical Analyst	CNN

Honors and Prizes

1990	Phi Beta Kappa	Washington University in St. Louis
------	----------------	------------------------------------

1990	Summer Research Fellowship	National Institutes of Health
2000	Edward H. Kass Award for Clinical Excellence in Infectious Disease	Massachusetts Infectious Disease Society
2002	Maxwell Finland Award for Research Excellence in Infectious Disease	Massachusetts Infectious Disease Society
2005	Top 10 Papers of the Year	National Institute of Mental Health
2006	Top 10 Papers of the Year	National Institute of Allergy and Infectious Disease
2007	Paper of the Year	MGH, Institute of Technology Assessment
2008	Partners in Excellence	Partners Health Care Award for Outstanding Community Contributions
2008	HIVMA Emerging Leader in HIV Research	Infectious Disease Society of America
2008	Clinical Infectious Diseases	Top 10% of Reviewers
2008	Annals of Internal Medicine	Top 10% of Reviewers
2010	Young Mentor Award	Harvard Medical School
2010	Stephen Krane Award (Young Investigator)	Massachusetts General Hospital, Department of Medicine
2010	#1 and #2 Comparative Effectiveness Papers of the Year	National Institute of Allergy and Infectious Diseases
2011	Member	American Society of Clinical Investigation (ASCI)
2012	Member	Johns Hopkins Society of Scholars
2014	Oswald Avery Award	Infectious Disease Society of America
2015	MGH Research Scholar	Massachusetts General Hospital
2016	Clifford A. Barger Mentorship Award	Harvard Medical School
2016	IAPAC 150, honoring those 150 people who have influenced IAPAC's mission, vision and programs over 30 years	The International Association of Providers of AIDS Care (IAPAC)
2017	Mentor with Distinction	Massachusetts General Hospital
2018	John F. Enders Distinguished Lectureship	IDWeek 2018, San Francisco, CA
2018	John T. Potts, Jr. MD Faculty Mentoring Award	Center for Faculty Development, MGH
2021	Alumni Day Award for Excellence	Yale School of Public Health
2021	Terezín Legacy Award	Terezín Music Foundation
2021	<i>Georgia Trend</i> 100 Influential Georgians List	Georgia Institute of Technology
2022	Honorary Doctor of Science Degree	Worcester Polytechnic Institute
2022	National Public Health Service Award	Massachusetts League of Community Health Centers
2022	The '50 Most Influential Clinical Executives,' according to Modern Healthcare	Advisory Board
2022	Distinguished Member of Short List for the Dr Gertrude Herzfeld International Jewish Woman of the Year Prize for Health	Edinburgh Jewish Cultural Centre at the Royal College of Surgeons of Edinburgh
2022	Impact Leader of the Year Award	FedHealthIT100

Report of Funded and Unfunded Projects

Funding Information

Past

- 1999-2000 AIDS Clinical Research Training Fellowship
NIAID T32 AI07433
Research Fellow
The project funded was to examine the cost-effectiveness of treatment for primary HIV infection.
- 2000-2001 Post-Doctoral Fellowship in Health Services Research
AHRQ T32 HS00020
Research Fellow
The project funded was to model the impact of treating primary HIV infection on clinical outcomes, life expectancy and viral resistance.
- 2001-2002 The Center for AIDS Research Junior Investigator Award
NIAID P30 AI42851
PI
Treatment Models for Primary HIV Infection
- 2001-2003 Massachusetts Department of Public Health
Co-PI
Routine Voluntary HIV Counseling and Testing in the State of Massachusetts
- 2001-2006 Mentored Patient-Oriented Career Development Award
NIAID K23 AI01794
PI
Treatment Models for Primary and Chronic HIV Infection
- 2002-2004 Claflin Distinguished Scholar Award, The Office of Women's Careers, Massachusetts General Hospital
PI
The Impact of Prevention and Treatment Interventions on the HIV Epidemic in Africa
- 2005-2009 Doris Duke Charitable Foundation, Clinical Scientist Development Award
PI
Impact and Value of Routine HIV Testing in South Africa
- 2008-2013 PROMISE (Promoting Mother to Infant Survival Everywhere)
NIH/IMPAACT Trial Network
Co-investigator (PI: Freedberg)
The focus of this study will be to conduct cost-effectiveness studies alongside the PROMISE Trial using the CEPAC model and a newly developed pediatric HIV model.
- 2008-2013 Efficacy of CBT for Adherence and Depression in HIV Care Settings
NIH/NIMH 1R01MH084757
Co-Investigator (PI: Safren)

This project will enroll in a randomized trial of provider- vs. counselor-based routine, voluntary HIV testing in the Emergency Department setting to evaluate the effectiveness and cost-effectiveness of these interventions at HIV case identification and linkage to care.

- 2009-2012 Economics of Treatment and Prevention Services for Drugs and Alcohol
NIH/NIMH, R01
Co-Investigator (PI: Schackman)
The goals of this project are to use the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) computer simulation model to aid in the analysis of the economic effectiveness for treatment and prevention of drug and alcohol abuse.
- 2010-2014 Modeling the Impact of HIV Prevention Interventions
NIH/NIMH, R01
Co-Investigator (PI: Seage)
The goals of this project are (1) to build a stochastic, agent-based HIV transmission model which captures the population effects of the transmission dynamics of HIV; (2) to evaluate the impact of primary, secondary and combination HIV prevention interventions on population level measures in South Africa; (3) to evaluate the impact of primary, secondary and combination HIV prevention interventions either alone or in combination, on population level measures in the U.S.
- 2010-2016 Linkage & Retention: A Randomized Trial to Optimize HIV/TB Care in South Africa
NIH/NIMH, R01
Co-Investigator (PI: Bassett)
The goal of this project is to conduct an intervention study examining alternative strategies for newly identified HIV-infected patients to effectively link to clinical care.
- 2011-2014 Evaluation of Treating Discordant Couples to Prevent Transmission
NIH/NIAID, R01 Supplement
Co-Investigator (PI: Freedberg)
The goal of this project is to work with the HPTN 052 team on an economic analysis of the clinical trial which showed that treating HIV serodiscordant couples early could dramatically decrease HIV transmission to the uninfected partner. This study will provide policy insights in terms of the overall impact of developing this strategy as a standard of care.
- 2012-2013 Novel Methods to Evaluate Infection Control Strategies
InHealth (2011D004925)
Co- Principal Investigator
This proposal aims to pioneer the application of discrete event simulation to examine and critically estimate the clinical, operational and economic value of nucleic acid testing applied to accurate identification of individuals who have cleared Vancomycin-resistant enterococcus (VRE) colonization.
- 2012-2020 Impact Evaluation of Combination HIV Prevention Interventions in Botswana
Centers for Disease Control and Prevention (RFA GH11-006/U2GGH001911)
Site Principal Investigator (PI: Essex) (\$682,653)

The Cost-Effectiveness of Preventing AIDS Complications (CEPAC) group and HSPH will evaluate the impact and cost-effectiveness of combination HIV prevention strategies in Botswana. The prevention strategies to be studied include enhanced HIV testing and counseling (HTC), adult male circumcision (MC), antiretroviral therapy (ART) for individuals qualifying by local guidelines, ART-for-prevention in individuals with high HIV load (regardless of CD4), and prevention of mother-to-child transmission (PMTCT).

- 2014-2016 Prevention Policy Modeling Lab
Centers for Disease Control and Prevention, U38PS004644
Co-Investigator (PI: Salomon)
The goal of this project is to conduct health and economic modeling to inform decision-making on HIV, hepatitis, STD, TB and school health at national, state and local levels, in partnership with the National enter for HIV/AIDS Viral Hepatitis, STD and TB Prevention.
- 2014-2017 Optimising Testing and Linkage to Care for HIV Across Europe
European Commission (INSERM, prime)
Co-Investigator (PI: Grarup, *et al.*)
Workplan #6: The cost-effectiveness of HIV testing strategies in priority groups and regions. The objective of this workplan is use a computer, microsimulation model of HIV disease to estimate the survival benefits, costs, and cost-effectiveness of innovative HIV testing strategies in Europe.
- 2014-2020
(NCE) Novel Approaches to the Design and Evaluation of Combination HIV Prevention
NIH/NIAID, R01AI112340
Site Principal Investigator (PI: Paltiel) (\$1,167,245)
This study will use novel mathematical modeling methods to examine combination HIV prevention and new methods to examine the value of economic incentives to improve HIV outcomes including linkage, retention and adherence.
- 2015-2018 Rapid Urine-Based Screening for Tuberculosis to Reduce AIDS-Related Mortality in Hospitalized Patients in Africa (STAMP) Trial
Medical Research Council
Site Principal Investigator (PI: Lawn) (\$277,327)
The main aim of this work is to determine whether use of a fundamentally new approach to rapid diagnostic screening for HIV-associated tuberculosis (TB) using novel, high-sensitivity urine-based testing reduces all-cause mortality among HIV-infected patients requiring admission to medical wards in hospitals in southern Africa.
- 2016-2017 Optimizing Infant HIV Testing Strategies: Using Modeling to Inform Guidelines and Program Planning
World Health Organization, 2016/655647-0
Co-Investigator (PI: Ciaranello)
The overall objective is to conduct model-based analyses to inform the development of future normative guidance and the design of testing strategies tailored to the epidemic setting.

- 2016-2018 The Cost-Effectiveness of Interventions to Promote Medication Adherence in Type 2 Diabetes
NIH/NIDDK, P30DK057521, Boston Area Diabetes Endocrinology Research Center Pilot & Feasibility Grant
Project PI (Grant PI: Avruch) (\$30,000)
The goal of this pilot project is to examine the clinical and economic outcomes of diabetes prevention and treatment through the development and validation of a novel diabetes simulation model.
- 2018-2020
(NCE) Cost-effectiveness of Preventing HIV Complications (supplement: The Clinical and Economic Impact of Alzheimer's Disease and Alzheimer's Disease-Related Dementias in People with HIV)
NIH/NIAID, R01AI042006
Co-Investigator (PI: Freedberg)
The purpose of this Administrative Supplement is to develop an expansion of the CEPAC-US model to: 1) investigate Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), including clinical outcomes, quality of life, and associated costs and 2) project lifetime clinical, quality of life, and economic outcomes associated with AD/ADRD among people with HIV in the United States.
- 2006-2020 NIH Adult AIDS Clinical Trials Group (AACTG)
NIH/NIAID, U01AI068636
Co-Investigator (PI: Currier)
The goal of this project is to conduct cost-effectiveness studies alongside selected ACTG trials using the CEPAC model. Modeling studies will use efficacy and cost data from the clinical trials to project long-term clinical outcomes and costs, and to evaluate the cost-effectiveness of the clinical trial interventions.
- 2016-2021 Global TravEpiNet: Global Travelers' Health Surveillance, Applications, and Consortium Centers for Disease Control and Prevention, U01CK000175
Co-Investigator (PIs: Ryan/LaRocque)
This project supports web tools to facilitate optimizing health advice and immunization approaches for global international travelers, and incorporates a national consortium of global travelers' health research centers to assess vaccination strategies.
- 2016-2021 The Silver Tsunami: Projecting Multimorbidity, Polypharmacy, and Health Care Costs for Those Aging with HIV in the US
NIH/NIA, R01AG053100 (Johns Hopkins University, prime)
Site Principal Investigator (PI: Althoff) (\$485,067)
The proposed research will use simulation modeling to project the annual costs of non-HIV-related healthcare among people living with HIV/AIDS and in care in the US.
- 2020-2021 Cost-effectiveness of long-acting injectable HIV pre-exposure prophylaxis among men who have sex with men and transgender women in the United States: a collaboration with the HPTN 083 investigators
NIH/FHI 360
Role: PI (\$250,456)

Using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model, we will simulate three PrEP strategies: CAB-LA, tenofovir disoproxil fumarate + emtricitabine (F/TDF), and tenofovir alafenamide + emtricitabine (F/TAF) among men who have sex with men (MSM) and transgender women (TGW) in the United States.

- 2011-2025 Novel Methods to Inform HIV/TB Clinical Trial Development
NIH/NIAID, R37AI093269-MERIT
Principal Investigator (\$6,830,910)
In collaboration with the ACTG, the focus of this study will be to apply novel microsimulation methods to evaluate trials under development for efficiency and to optimize the value of trials that are ultimately conducted.
- 1998-2025 Cost-effectiveness of Preventing HIV Complications.
National Institute of Allergy and Infectious Diseases, R01AI42006
Co-Investigators (PI: Freedberg)
The purpose of the proposed research is to build on the Cost-effectiveness of Preventing AIDS Complications (CEPAC) model with results that continue to inform national and international clinical guidelines. We propose to capitalize on the unique strengths of mathematical modeling to inform efforts to end the HIV epidemic in the US.
- 2004-2023 Optimizing HIV Care in Less Developed Countries
NIH/NIMH, R37AI058736 MERIT
Co-Investigator (PI: Freedberg)
This study will assess the clinical impact, cost, and cost-effectiveness of alternative strategies for HIV management in South Africa, Brazil, India, and Côte d'Ivoire.
- 2014-2024 Innovation Across the Spectrum of Pediatric HIV Care
NIH/NICHD, R01HD079214
Co-Investigator (PI: Ciaranello)
This project will expand the CEPAC-Pediatric model in Côte d'Ivoire, South Africa, and Zimbabwe. Aims include projecting the long-term clinical outcomes, costs-, and cost-effectiveness of HIV diagnostic testing strategies, ART initiation strategies, and approaches to monitoring and switching ART regimens.
- 2015-2023 Novel Approaches to Clinical Trial Design and Development
MGH Executive Committee on Research, MGH Research Scholar Award
Principal Investigator (\$434,785)
The purpose of this project is to use novel microsimulation methods to inform the prioritization, development, and policy value of randomized controlled trials. Dr. Walensky will extend and expand this novel modeling methodology to other research areas where MGH leads on a national level, specifically amyotrophic lateral sclerosis and diabetes.
- 2020-2025 Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes
NIH/NIDA R01DA050482
Co-Investigator (PI: Reddy)

This project will combine an integrated cost-effectiveness model of tobacco, HIV, and tuberculosis care with tobacco-related findings from a population-based cohort in South Africa to project clinical and economic outcomes and cost-effectiveness of tobacco cessation interventions in HIV care. The overall goal is to promote an evidence-based approach to decisions around the integrated health care and services for the overlapping tobacco, HIV, and tuberculosis epidemics.

Report of Teaching and Training

Teaching of Students in Courses

Prior to Harvard Appointment

2001	Decision Analysis in Clinical Research 50-75 Graduate Students	Harvard School of Public Health Teaching Assistant 20 hours prep time, 20 hours contact time
2002	Faculty Seminar, "Modeling the HIV Epidemic in Africa," Infectious Disease Epidemiology 15 Graduate Students	Harvard School of Public Health Lecturer 3 hours prep time, 2 hours contact time
2007-2021	Epidemiology 294, Screening, "HIV Screening" 20 Graduate Students	Harvard School of Public Health Guest Lecturer 4 hours prep time, 1 lecture
2007-2021	Program in Clinical Effectiveness 8 Graduate Students	Harvard School of Public Health Guest Faculty, no prep time, 1 interactive session
2005-2009	Health Services Research Methods and Policy, "Decision Analysis and Cost-effectiveness Analysis" 10 Graduate Students	Boston University School of Public Health Guest Lecturer 2 hours prep time, 1 lecture
2010	Epidemiology 764: AIDS HIV Care in the US and Africa: From Clinical Trials and Cohorts to Policy 20 Graduate Students	Boston University School of Public Health Guest Lecturer 5 hours prep time, 1 lecture
2011	Epidemiology 256, Design and Conduct of HIV Prevention Trials 25 Graduate Students	Guest Lecturer, 10 hours prep time, 1 lecture

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

2003	Primary Care Research Curriculum, "Decision Analysis/Cost-effectiveness Analysis" 15 Residents	Massachusetts General Hospital Lecturer 3 hours prep time, 4 lectures
2004	Center of Excellence in Minority Health Research Seminar Series, "Cost-	Harvard Medical School

	effectiveness and Decision Analysis Research” 20 Fellows	3 hours prep time, single 2-hour lecture
2004-2021	Minority Center of Excellence Research Seminar Series, 30 Physicians	Harvard Medical School 3 hours prep time, 1 lecture
2004-2021	Tools of Human Investigation, “Decision analysis and Cost-effectiveness Analysis” 15 Residents	Massachusetts General Hospital, 2 hours prep time, 4 lectures/year
2006-2021	Writing a K Award? Want to get it funded? 90 Fellows/Graduate Students	Center for AIDS Research, HMS 10 hours prep time/1 2-hour lecture/year
2007-2009	Decision Analysis/Cost-effectiveness Analysis	Massachusetts General Hospital Clinical Research Program, Design and Conduct of Clinical Trials
2008	30 Fellows/Physicians Informing HIV Policy in Africa: Results from the CEPAC International Model	5 hour prep time, 1 lecture Institute for Technology Assessment: PCORT Seminar
2009-2021	10 Fellows/Graduate Students Applying for an NIH Career Development Award	5 hours prep time/1 1-hour lecture Massachusetts General Hospital, Clinical Research Program
2009-2021	50 Fellows/Graduate Students Career Development Plans: Introductory Grant Course	10 hours prep time, 1 45 minute lecture/year Brigham and Women’s Hospital/Children’s Hospital Clinical Research Program
2009	75 Fellows/Graduate Students When to Start ART in Resource-Poor Settings	3 hours prep time, 1 30 minute lecture/year Massachusetts General Hospital, Global Health Resident Report
2011	15 Residents Scaling up WHO Recommendations for HIV Therapy in Resource-Limited Settings 15 Residents	3 hours prep time, 1 30-minute lecture Massachusetts General Hospital, Global Health Resident Report 3 hours prep time, 1 30-minute lecture

Clinical Supervisory and Training Responsibilities

2001-2021	Attending Infectious Disease Service Brigham and Women’s Hospital	Full-time, 6 weeks/year
2002	Faculty Mentor Medical House staff Brigham and Women’s Hospital	3 meetings/year
2003	Faculty Mentor Medical House staff Massachusetts General Hospital	5 meetings/year
2010-2012	Faculty Mentor, Scholars in Clinical Science Program Harvard Medical School	2 fellows, 4 meetings/year

Laboratory and Other Research Supervisory and Training Responsibilities

Formally Supervised Trainees

Charles Holmes, MD, MPH, Director and CEO of the Centre for Infectious Disease Research in Zambia
Published 2 manuscripts and received a K-award

Ingrid Bassett, MD, MPH, Associate Professor in Medicine, Harvard Medical School (Infectious Disease)
Mentored many publications (including 2010 Top Comparative Effectiveness paper of the Year at NIAID), K-award, R01, R21

Bisola Ojikutu, MD, Director, Office of International Program, Harvard Center for AIDS Research
Assisted with single publication

Benjamin Linas, MD, MPH, Instructor in Medicine, Harvard Medical School (Infectious Disease)
Co-authored several publications

Melissa Bender, MD, Assistant Professor University of Washington Medical Center
Co-mentored on a single project during infectious disease research fellowship that resulted in publication

Alethea McCormick, ScD, Post-doctoral Research Fellow, Harvard School of Public Health
Mentored on a publication for her PhD thesis; work continues on a dynamic simulation model

Jennifer Millen, MD, MPH, Senior Resident, Brigham and Women's Hospital (Emergency Medicine)
Senior-authored a review of HIV screening that led to publication

Muriel Jean-Jacques, MD, MPH, Assistant Professor, Northwestern University School of Medicine (Internal Medicine)
Mentored on senior resident project that resulted in publication

Hazel Williams-Roberts, MD, Director, Community Based Health Services, Ministry of Health, St. Kitts, West Indies
Mentored on a summer clinical effectiveness project that resulted in publication

Christian Arbelaez, MD, MPH, Assistant Professor, Harvard Medical School (Emergency Medicine)

Mentored on areas of clinical research in the Emergency Department setting; senior-authored two papers of his that led to publication

Andrea Ciaranello, MD, MPH, Assistant Professor in Medicine, Harvard Medical School (Infectious Disease)

Mentored on numerous publications and her K-award, Claflin Award, Elizabeth Glaser Pediatrics AIDS Foundation and March of Dimes Foundation Award, R01

Michael April, DPhil, Rhodes Scholar, Oxford University, Assistant Residency Program Director for Research, San Antonio Uniformed Services Health Education Consortium, (Emergency Medicine)

Co-mentored his DPhil research while at Oxford and have continued in this role through mentoring his senior thesis at HMS and additional papers while he is a house officer; these activities have resulted in 3 publications

Mai Pho, MD, Clinical Associate of Medicine, University of Chicago (Infectious Disease)

Mentored during research fellowship; manuscript published

Mary Pisculli, MD, MPH

Mentored on research paper that resulted in publication

Julie Levison, MD, MPhil, Instructor in Medicine, MGH (Infectious Disease)

Mentored during her research fellowship; manuscript published; K award

Jason Andrews, MD, Assistant Professor of Medicine, Stanford (Infectious Disease)

Mentored during research fellowship; 3 papers published; K award mentor, R01, DP2

Erica Shenoy, MD, PhD, Instructor in Medicine, MGH (Infectious Disease)

Mentored during research fellowship and as junior faculty; 11 manuscripts published; K award co-mentor

Kelli O’Laughlin, MD, MPH Instructor in Medicine, BWH (Emergency Medicine)

Mentored for a HIV screening project in a refugee camp in rural Uganda; recipient of 2012 CFAR Feasibility Award; manuscript published; K award funded 2016

Emily Hyle, MD, Instructor in Medicine, MGH (Infectious Diseases)

Mentored as junior faculty; Recipient of 2014 CFAR Scholar Award; 5 manuscripts published; K award funded 2016

Kimberly Blumenthal, MD, Instructor in Medicine, MGH (Allergy/Immunology Fellow)

Mentored as junior faculty; K award funded 2016

Krishna Reddy, MD, Research Fellow, MGH (Pulmonary/Critical Care Fellow)

Mentored during research fellowship; K award funded 2016

Pooyan Kazemian, PhD, Research Fellow, MGH (Operations Researcher)

Mentored on a model of diabetes mellitus; anticipated K submission 2019

Amir Mohareb, MD, Research Fellow, MGH (Infectious Diseases)

Mentored during research fellowship

Formal Teaching of Peers (e.g., CME and other continuing education courses)

2001	Cost-Effectiveness in HIV Care AIDS Medicine: An Intensive Course	1 lecture (5 hrs prep time) Harvard Medical School, Boston
2002	HIV in Women AIDS Medicine: An Intensive Course	1 lecture (10 hrs prep time) Harvard Medical School, Boston
2003	HIV in Women AIDS Medicine: An Intensive Course	1 lecture (10 hrs prep time) Harvard Medical School, Boston
2004	HIV in Women AIDS Medicine: An Intensive Course	1 lecture (10 hrs prep time) Harvard Medical School, Boston
2005	Current Controversies and Options in HIV Testing AIDS Medicine: An Intensive Course	1 lecture (10 hrs prep time) Harvard Medical School, Boston
2006	Current Controversies and Options in HIV Testing AIDS Medicine: An Intensive Course	1 lecture (10 hrs prep time) Harvard Medical School, Boston
2008	Current Controversies and Options in HIV Testing AIDS Medicine: An Intensive Course	1 lecture (10 hrs prep time) Harvard Medical School, Boston
2007	Implementation of New HIV Testing Guidelines HIV Management, The New York Course	Half-hour lecture (5 hrs prep time) Albert Einstein College of Medicine, New York
2009	HIV Care in the US: From Cohorts & Trials to Policy International AIDS Society-USA	Half-hour lecture (hrs prep time) Chicago
2011	Top Ten Mentoring Tips Strategies that Work for Successful Mentoring: A Faculty Development Course for Mentors	Harvard Medical School, Boston 100 Faculty Members Half-hour lecture (3 hrs prep time)

Local Invited Presentations *(To my knowledge, none of these talks were industry-sponsored events)*

2005	Routine, Voluntary HIV Testing: A Clinical and Economical Evaluation of National Guidelines/Medical Grand Rounds Department of Medicine, Massachusetts General Hospital
2006	The Case for Routine HIV Testing/Emergency Medical Grand Rounds Department of Emergency Medicine, Brigham and Women's Hospital
2007	HIV Testing and the USHER Experience/ HIV Journal Club Division of Infectious Disease, Brigham and Women's Hospital
2008	HIV Testing: Making the Revised Guidelines a Reality New England AIDS Education Training Center (NEAETC)
2008	HIV Testing and the USHER Experience/ HIV Journal Club Division of Infectious Disease, Brigham and Women's Hospital
2008	Universal Screening for HIV in the ER: The USHER Experience/ HIV Clinical Conference Division of Infectious Disease, Massachusetts General Hospital
2008	Informing HIV Policy in Africa: The Question of When to Start/ Research Conference Institute of Health Policy, Massachusetts General Hospital
2010	HIV Care in the US and Africa: From Cohorts and Trials to Policy/ Medical Grand Rounds Department of Medicine, Massachusetts General Hospital

Report of Regional, National and International Invited Teaching and Presentations

Invited Presentations and Courses

Regional

2003	Think HIV/ Medical Grand Rounds Cambridge Hospital, Cambridge, MA
2014	Boston Medical Center, Division of Infectious Disease, Grand Rounds
2014	Garabedian Lecture, Grand Rounds Mount Auburn Hospital, Cambridge, MA
2015	MGH Research Administrator's Retreat, Boston, MA
2018	And Sometimes Things Go Sideways, Harvard Medical School Leadership Development Course

National

2003	Using Cost-effectiveness Analysis to Set Priorities in HIV Counseling, Testing and Referral/ Invited Lecture Turning Research into Progress (TRIP) Conference Centers for Disease Control and Prevention Atlanta, GA
2003	The Clinical Impact and Cost-effectiveness of HIV CTR: From Guidelines to Standard of Care/ Invited Lecture Centers for Disease Control and Prevention, Atlanta, GA
2004	Scaling Up Antiretroviral Therapy in Resource Poor Countries: the Impact of Speed on Survival, International AIDS Conference/ Invited Lecture, Satellite Symposium National Institute on Drug Abuse, Mexico City, Mexico
2005	The Case for Routine Voluntary HIV Testing: Health Benefits and Cost-effectiveness/ Invited Lecture National Institute on Drug Abuse, Bethesda, MD
2005	The Case for Routine HIV Testing/ Invited Lecture, National Press Club National Institute on Drug Abuse, Washington, DC
2006	Opportunities for Improving HIV Diagnosis, Prevention, and Access to Care in the US/ Invited Presentation HIV Summit, Washington, DC
2007	The Johns Hopkins Hospital/Medical Grand Rounds Baltimore, MD
2008	Montefiore Medical Center/ Infectious Disease Grand Rounds New York, NY
2010	Center for AIDS Research, University of Pennsylvania/ CFAR Conference Philadelphia, PA
2010	IDSA: Center for Global Health/ HIV Testing and Treatment: The Magnitude of the Impact Press Conference, The Capitol, Washington, DC
2010	Opportunities for Improving HIV Diagnosis, Prevention, and Access to Care in the US/ Invited Presentation: Test and Treat, Clinical Importance HIV Summit, Washington, DC
2010	Opportunities for Improving HIV Diagnosis, Prevention, and Access to Care in the US/Invited Presentation: Test and Treat: Policy and Economic Impact HIV Summit, Washington, DC

2011 University of Alabama/CFAR Symposium
Birmingham, AL

2011 Center for AIDS Research, University of North Carolina/CFAR Symposium
Chapel Hill, NC

2012 Doris Duke Charitable Foundation: Clinical Scientist Meeting
Chicago, IL

2012 American Society of Clinical Investigation, New Member Selected Speaker
Chicago, IL

2012 DC D-Center for AIDS Research City-wide Seminar
Washington, DC

2012 NIAID Grand Rounds: Modeling in Infectious Diseases: Linking Clinical Research to
Outcomes and Policy
Bethesda, MD

2013 Johns Hopkins University School of Medicine, Center for AIDS Research, Baltimore, MD

2013 Albert Einstein College of Medicine, Montefiore Medical Center, Infectious Disease
Grand Rounds, Bronx, NY

2014 Medical University of South Carolina, Infectious Disease Grand Rounds, Charleston, SC

2014 Dr. Francis Collins, Advisory Council to the Director, Bethesda, MD

2014 Uniformed Services, University of the Health Sciences, Military Tropical Medicine
Course, Bethesda, MD

2014 Arthur Ashe Endowment AIDS Lecture, Cornell University, New York, New York

2015 Emory School of Medicine, ID Seminar, Atlanta, GA

2015 Forum for Women in Internal Medicine, Academic Women's Network, Washington
University in St. Louis, St. Louis, MO

2017 HIV and Cost Considerations: Entering a New Era...in the US, IDWeek, San Diego, CA

2018 Beth Israel Deaconess Medical Center, Robert C. Moellering Jr. Infectious Diseases
Visiting Professorship

2018 Enders Lecture: The Costs of the Drugs We Use: Branded, Generic and Why We Should
Care, IDWeek, San Francisco, CA

2019 Congressional Testimony: House Oversight and Reform Committee, Chairman Elijah
Cummings; HIV Prevention Drug: Billions in Corporate Profits After Millions in Taxpayer
Investments. May 16, 2019: <http://bit.ly/2JrI5Bw> <http://bit.ly/2Jo24ku>

2019 26th Annual Jesse Ibarra Jr, MD Lectureship, Finding the Way to the HIV Policy Table,
Baylor Scott & White Health, Texas A&M, November 2019, Temple, TX

2019 Kirby Lectureship, Dinner and Medical Grand Rounds Finding the Way to the HIV Policy
Table, University of Washington, Seattle, November 2019, Seattle Washington

2020 COVID-19 and Higher Education: What is the Test We Need to Open College Campuses?
MassCPR Diagnostics Working Group via Zoom, Boston, MA June 11, 2020

2020 COVID-19 and Higher Education: What is the Test We Need to Open College Campuses?
Yale University Reopening Committee via Zoom, June 19, 2020 and July 17, 2020

2020 COVID-19 and Higher Education: What is the Test We Need to Open College Campuses?
University of Southern California, Reopening Committee via Zoom, June 26, 2020

2020 COVID-19 Conversations: Managing Ongoing Surges: Lessons from the Front Lines.
American Public Health Association and National Academy of Medicine, Moderator via
Zoom, July 29, 2020

2021 Resilience and Recovery: Health Care, Vaccines and The Road Back from COVID-19
The 19th, Keynote Conversation, via Zoom, March 11, 2021

2021 2021 Association of Schools and Programs of Public Health Annual Meeting, Plenary Session, via Zoom, March 25, 2021

2021 Allocating Resources during Epidemics and Pandemics

2021 NIH NIAID Grand Rounds Grand Rounds via Zoom, April 2, 2021

2021 Opening Plenary Session: Welcome to the 2021 National Tribal Public Health Summit

2021 National Indian Health Board, Plenary via Zoom, April 27, 2021

2021 Pediatric Academic Societies 2021 Virtual Meeting, Keynote Address, via Zoom (taped remarks), April 30, 2021

2021 COVID-19: Lessons Learned. The Jim and Midge Breeden Lecture, The American College of Obstetricians Gynecologists Annual Meeting, Clinical Plenary via Zoom, May 1, 2021

2021 Northeastern University Commencement, May 8, 2021

2021 Keck School of Medicine, University of Maryland Commencement Celebration, May 13, 2021

2021 New York University's School of Public Health Virtual Graduation, May 20, 2021

2021 Osler Medical Residency, Johns Hopkins Hospital Appreciation End of Year Celebration, May 21, 2021

2021 Atlanta Summit on Global Health: Race to Beat COVID-19

2021 World Affairs Council of Atlanta, Keynote, via Zoom, June 2, 2021

2021 The Virtual National Health Equity Summit Closing Keynote Address, via Zoom, June 10, 2021

2021 Bridging the Public's Health – COVID-19 and Beyond

2021 Council of State and Territorial Epidemiologists 2021 Annual Conference, Keynote Address, via Zoom on June 16, 2021

2021 Forum 21 Resilience Rising

2021 National Forum for Black Public Administrators, Keynote Address via Zoom, June 25, 2021

2021 National Association of Local Boards of Health Annual Conference Keynote Address via Zoom, July 16, 2021

2021 Health Action Alliance Business Townhall on Childhood Vaccination Keynote Address via Zoom, July 19, 2021

2021 The Business Council for International Understanding Charting the Path Forward: Recommitting to Global HIV/AIDS Strategy Keynote Address via Zoom, July 19, 2021

2021 Massachusetts Institute of Technology course on COVID-19, SARS-COV-2 and the Pandemic via Zoom, October 5, 2021

2021 2021 Adolescent Medicine Trials Network for HIV/AIDS Interventions National Meeting Keynote Address via Zoom, October 6, 2021

2021 2021 Annual Influenza/Pneumococcal Disease News Conference Keynote Address via Zoom, October 7, 2021

2021 National Institutes of Health 57th Office of AIDS Research Council Meeting Keynote Address via Zoom, October 28, 2021

2021 National Centers for AIDS Research Scientific Symposium Keynote Address via Zoom, November 4, 2021

2022 Conference on Retroviruses and Opportunistic Infections 2022 - Opening Session Special Presentation via Zoom, February 13, 2022

2022 Wednesday with WashU: The Power of Arts and Sciences Week Webinar Series at Washington University in St. Louis, March 2, 2022.

2022 Gerald Medoff Visiting Professor at Washington University in St. Louis, March 3, 2022

- 2022 American Epidemiological Society Langmuir Lecture via Zoom March 10, 2022
- 2022 2022 Lectures Committee at Princeton University: Navigating the Pandemic's Political Landscape as a Health Professional, March 24, 2022
- 2022 Cedars-Sinai Grand Rounds Presentation, May 6, 2022
- 2022 Regis College Commencement, May 7, 2022
- 2022 Worcester Polytechnic Institute Undergraduate Commencement Ceremony, May 14, 2022
- 2022 Johns Hopkins Bayview Medical Grand Rounds 19th Annual Miller Lecture, May 17, 2022
- 2022 Johns Hopkins School of Medicine Reunion Symposium Keynote Address, June 3, 2022
- 2022 Aspen Ideas Festival 2022 Editorial Session: Protecting the Public's Health, June 23, 2022
- 2022 Aspen Ideas Festival 2022 CDC Foundation Presents: Feeling the Heat: The Climate and Health Challenge, June 24, 2022
- 2022 University of Virginia Hayden-Farr Lecture in Virology and Epidemiology, October 26, 2022
- 2022 University of Maryland School of Medicine Pincoffs Lecture in Medicine, November 16, 2022
- 2022 Bloomberg American Health Summit Keynote Address, December 6, 2022
- 2023 Virtual Public Health Grand Rounds, University of Oklahoma, Hudson College of Public Health, February 9, 2023
- 2023 Conference on Retroviruses and Opportunistic Infections "A Call to Action for New Investigators: Opportunities in Research and Public Health", February 19, 2023
- 2023 The BA-MD Distinguished Lecture Series, Brooklyn College, March 31, 2023
- 2023 Rx and Illicit Drug Summit 2023 Editorial Session, April 12, 2023
- 2023 AAP/ASCI/APSA Meeting Plenary Session on Infectious Disease and Pandemics, April 22, 2023
- 2023 Boston University Chobanian & Avedisian School of Medicine Commencement, May 18, 2023.
- 2023 Marymount University College of Health and Education Commencement, May 21, 2023.
- 2023 John Hopkins University School of Medicine Convocation, May 24, 2023.

International

- 2004 The Missing Link: The Importance of Linkage to Care in the HIV Testing Paradigm/Symposium, Invited Lecture
Third International Conference on Urban Health, Boston, MA
- 2006 Three Million Years of Life Saved: The Survival Benefit of AIDS Therapies in the United States/ Invited Lecture
International Association of Physician's in AIDS Care (IAPAC), North American Sessions 2006, Chicago, IL
- 2006 Three Million Years of Life Saved: The Survival Benefit of AIDS Therapies in the United States, Decade of HAART/ Plenary Address
International Association of Physician's in AIDS Care (IAPAC), San Francisco, CA

2008	HIV Care in the US and Africa: From HIV Cohorts to Policy/The Richard Doll Seminar Invited Presentation Oxford University, Department of Public Health, Oxford, UK
2009	Cost-effectiveness of Laboratory Monitoring in Resource-Limited Settings/ Invited Symposium Speaker 5 th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa
2010	Changing Course: Stemming the Deadly Twin Epidemics of HIV and Tuberculosis/ Invited Press Conference Speaker The Center for Global Health Policy: IDSA/HIVMA, Washington, DC
2010	NIMH: HIV Testing: Global Challenges, Global Strategies, Global Impact/ Invited Symposium Speaker Preconference to: XVIII International AIDS Conference, Vienna, Austria
2010	Infectious Disease Society of America/ Invited Symposium Speaker Global HIV Prevention and Treatment: Test and Treat, Vancouver, Canada
2010	Infectious Disease Society of America/ Poster Rounds Discussant Group Leader: HIV, Vancouver, Canada
2011	Conference on Retroviruses & Opportunistic Infectious/ Plenary Speaker Cost-effectiveness in HIV Care: Understanding Value in a World of Limited Resources, Boston, MA
2011	Epidemics3/World AIDS Day Plenary HIV Care in the US and Africa: Model-based Analyses to Impact Policy, Boston, MA
2013	7 th Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention and Treatment. Understanding the Value of HIV Interventions: From Prevention to Generic ART. Amsterdam, Netherlands
2016	UN High Level Meeting on HIV/AIDS – STAC: The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa, New York, NY
2018	UNAIDS STAC Meeting: What is the Role of PrEP in an Era of 90-90-90? Boston, MA and Geneva, Switzerland
2019	International Workshop on HIV & Hepatitis Observational Databases (IWHOD): Leveraging HIV Cohorts to Influence Policy Athens, Greece
2020	COVID-19 and Higher Education: What is the test we need to open college campuses? Braun School of Public Health and Community Medicine, Hebrew University of Jerusalem, MASHAV Global COVID-19 Forum, via Zoom, Jerusalem, Israel, July 19, 2020

Report of Clinical Activities and Innovations

Current Licensure and Certification

1995	Diplomate, National Board of Medical Examiners
1998	Diplomate, American Board of Internal Medicine
1998	Licensure, Massachusetts Board of Registration in Medicine
2000	Diplomate, American Board of Internal Medicine, subspecialty of Infectious Disease
2010	Recertified-Diplomate, American Board of Internal Medicine, subspecialty of Infectious Disease

Practice Activities

2001-2021	Consult Service	Infectious Disease Inpatient consult service, Brigham and Women's Hospital and Massachusetts General Hospital	5-6 weeks/year, covering approximately 3-6 new consults and 15-20 follow-up patients per day.
2001	Outpatient clinic	Brigham and Women's Hospital	Outpatient infectious disease clinic provides primary and specialty care to approximately 50 HIV-infected patients.

Report of Scholarship

Publications

Peer reviewed publications in print or other media

1. **Walensky RP**, Rosenberg ES, Ferraro MJ, Losina E, Walker BD, Freedberg KA. Investigation of primary HIV infection in patients with positive heterophile antibody tests. *Clin Infect Dis*. 2001; 33:570-572.
2. Vidrih JA, **Walensky RP**, Sax PE, Freedberg KA. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. *Am J Med*. 2001; 111:192-194.
3. **Walensky RP**, Moore R. A case series of 59 patients with nocardiosis: presentation and outcomes. *Infect Dis Clin Pract*. 2001; 10:249-254.
4. **Walensky RP**, Losina E, Steger-Craven KA, Freedberg KA. Identifying undiagnosed HIV: the yield of routine, voluntary inpatient HIV testing. *Arch Intern Med*. 2002; 162:887-892.
5. **Walensky RP**, Paltiel AD, Freedberg KA. AIDS drug assistance programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States. *Clin Infect Dis*. 2002; 35:606-610.
6. **Walensky RP**, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR, Losina E, Zhang H, Islam R, Freedberg KA. Treatment of primary HIV infection: projecting outcomes of immediate, interrupted or delayed therapy. *J Acquir Immune Defic Syndr*. 2002; 31:27-37.
7. Holmes CB, Losina E, **Walensky RP**, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. *Clin Infect Dis*. 2003; 36:652-662.
8. Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR 3rd, Kimmel AD, **Walensky RP**, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. *Am J Med*. 2003; 115:632-641.
9. Losina E, Islam R, Pollock A, Sax PE, Freedberg KA, **Walensky RP**. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. *Clin Infect Dis*. 2004; 38:1613-1622.

10. **Walensky RP**, Losina E, Skolnik PR, Hall JM, Malatesta L, Barton GE, O'Connor CA, McGuire JF, Freedberg KA. Voluntary HIV testing as part of routine medical care, Massachusetts 2002. *Morb Mort Wkly Rep*. 2004; 53:523-526.
11. Bassett IV, Freedberg KF, **Walensky RP**. Two drugs or three? Balancing efficacy, toxicity, and resistance for occupational HIV post-exposure prophylaxis. *Clin Infect Dis*. 2004; 39:395-401.
12. **Walensky RP**, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GS, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: how good is good enough? *Vaccine*. 2004; 22:4044-4053.
13. **Walensky RP**, Losina E, Malatesta L, Barton GE, O'Connor CA, Skolnik PR, Hall JM, McGuire JF, Freedberg KA. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. *Am J Public Health*. 2005; 95:71-73.
14. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, **Walensky RP**. Expanded HIV screening in the United States – A cost-effectiveness analysis. *N Eng J Med*. 2005; 352:586-95.
15. **Walensky RP**, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD. Routine HIV testing: an economic evaluation of current guidelines. *Am J Med*. 2005; 118:292-300.
16. **Walensky RP**, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. *Med Dec Making*. 2005; 25:321-329.
17. Kimmel AD, Goldie SJ, **Walensky RP**, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. *Antivir Ther*. 2005; 10:41-52.
18. Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, **Walensky RP**. Cost-effectiveness of Enfuvirtide (ENF) in treatment-experienced patients with advanced HIV disease. *J Acquir Immune Defic Syndr*. 2005; 39:69-77.
19. Yazdanpanah Y; Losina E, Anglaret X, Goldie SJ, **Walensky RP**, Weinstein MC, Toure S, Smith HE, Kimmel AD, Zhang H, N'Dri-Yoman T, Salamon R, Kaplan JE, Freedberg KA. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients living with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. *AIDS*. 2005; 19:1299-1308.
20. Sax PE, Islam R, **Walensky RP**, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA. Should resistance testing be performed in treatment naïve HIV-infected patients? A cost-effectiveness analysis. *Clin Infect Dis*. 2005; 41:1316-1323.
21. Liddicoat RV, Losina E, Kang M, Freedberg KA, **Walensky RP**. Refusing HIV testing in an urgent care setting: results from the "Think HIV" program. *AIDS Patient Care STDS*. 2006; 20:84-92.

22. Liddicoat RV, Zheng H, Internicola J, Werner BG, Kazianis A, Golan Y, Rubinstein EP, Freedberg KA and **Walensky RP**. Implementing a routine, voluntary HIV testing program in a Massachusetts county prison. *J Urban Health*. Nov 2006;83(6):1127-31. 10.1007/s11524-006-9095-9.
23. Linas B, Zheng H, Losina E, **Walensky RP**, Freedberg KA. Assessing the impact of federal HIV education and prevention spending. *Am J Pub Health*. 2006; 96:1038-1043.
24. **Walensky RP**, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The survival benefit of AIDS treatment in the United States. *J Infect Dis*. 2006; 194:11-19.
25. Holmes CB, Zheng H, Martinson NA, Freedberg KA, **Walensky RP**. Optimizing treatment for HIV-infected South African women exposed to single-dose Nevirapine: balancing efficacy and cost. *Clin Infect Dis*. May 7 2019;170(9):614-625. 10.7326/m18-3358.
26. Cohen T, Lipsitch M, **Walensky RP**, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-TB co-infected populations. *Proc Natl Acad Sci*. 2006; 103:7042-7047.
27. Losina E, Anglaret X, Yazdanpanah Y, Toure S, Seage GR, N'Dri-Yoman T, **Walensky RP**, Dakoury-Dogbo N, Goldie SJ, Messou KE, Weinstein MC, Salamon R, Freedberg KA. The impact of a history of opportunistic diseases on chronic HIV mortality in HIV patients in Côte d'Ivoire. *S Afr Med J*. 2006; 96:526-529.
28. Wertheimer BZ, Freedberg KA, **Walensky RP**, Yazdanpanah Y, Losina E. Therapeutic monitoring in HIV treatment: a literature review. *HIV Clin Trials*. 2006; 7:59-69.
29. Schackman BR, Gebo KA, **Walensky RP**, Losina E, Muccio TM, Sax PE, Weinstein MC, Seage GR, Moore RD, Freedberg KA. The lifetime cost of current HIV care in the United States. *Med Care*. 2006; 44:990-7.
30. Linas BP, Zheng H, Losina E, Rockwell A, **Walensky RP**, Cranston K, Freedberg KA. Optimizing resource allocation in United States AIDS drug assistance programs. *Clin Infect Dis*. 2006; 43:1357-64.
31. **Walensky RP**, Paltiel AD. Rapid HIV testing at home: does it solve a problem or create one? *Ann Intern Med*. 2006; 145:459-62.
32. Paltiel AD, **Walensky RP**, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. *Ann Intern Med*. 2006; 145:797-806.
33. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, **Walensky RP**, Smith HE, Kimmel AD, Holmes CB, Kaplan JE, Freedberg KA. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Côte d'Ivoire. *N Engl J Med*. 2006; 355:1141-53.

34. Losina E, **Walensky RP**, Geller A, Beddingfield FC, Wolf LL, Gilchrist BA, Freedberg KA. Visual screening for malignant melanoma: a cost-effectiveness analysis. *Arch Dermatol*. 2007; 143:21-28.
35. Wolf LL, **Walensky RP**. Testing for HIV infection in the United States. *Curr Infect Dis Rep*. 2007; 9:76-82.
36. McCormick AW, **Walensky RP**, Lipsitch M, Losina E, Hsu H, Weinstein MC, Paltiel AD, Freedberg KA, Seage GR. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. *Clin Infect Dis*. 2007; 44:1115-22.
37. **Walensky RP**, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA. HIV drug resistance surveillance for prioritizing treatment in resource limited settings. *AIDS*. 2007; 21:973-982.
38. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KA, **Walensky RP**. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. *AIDS*. 2007; 21:(S117-1228).
39. **Walensky RP**, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and care in the United States. *Clin Infect Dis*. 2007; 45 S4:S248-54.
40. Bassett IV, Giddy J, Nkera J, Wang B, Losina E, Lu Z, Freedberg KA, **Walensky RP**. Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. *J Acquir Immune Defic Syndr*. 2007; 46:181-6.
41. Yazdanpanah Y, Vray M, Meynard JL, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, **Walensky RP**, Dalban C, Sax PE, Girard PM, Freedberg KA. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. *HIV Med*. 2007; 8:439-50.
42. Millen JC, Arbelaez C, **Walensky RP**. Implications and impact of the Centers for Disease Control and Prevention (CDC) new HIV testing guidelines. *Curr Infect Dis Rep*. 2008; 10:157-63.
43. Waisbrain SE, Bowles H, Zhou KH, Emans SJ, Goldberg C, Gould S, Levine D, Lieberman E, Loeken M, Longtine J, Nadelson C, Patenaude AF, Quinn D, Randolph AG, Solet JM, Ullrich N, **Walensky R**, Weitzman P, Christou H. Gender differences in research grant applications and funding outcomes for medical school faculty. *J Womens Health (Larchmt)*. 2008; 17:207-214.
44. Ojikutu B, Zheng H, **Walensky RP**, Lu Z, Losina E, Giddy J, Freedberg KA. Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. *S Afr Med J*. 2008; 98:204-8.
45. Jean-Jacques M, **Walensky RP**, Aaronson WH, Chang Y, Freedberg KA. Late diagnosis of HIV infection at two academic medical centers: 1994-2004. *AIDS Care*. 2008;17:1-7.

46. **Walensky RP**, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana M, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. *J Infect Dis*. 2008; 197:1324-32.
47. Bassett IV, Farel C, Szmuiłowicz ED, **Walensky RP**. AIDS drug assistance programs in the era of routine HIV testing. *Clin Infect Dis*. 2008; 47:695-701.
48. Bassett IV, Giddy J, Wang B, Lu Z, Losina E, Freedberg KA, **Walensky RP**. Routine, voluntary HIV testing in Durban, South Africa: predictors of HIV infection. *HIV Med*. 2008; 9:863-867.
49. Schackman BR, Scott CA, **Walensky RP**, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. *AIDS*. 2008; 22:2025-33.
50. **Walensky RP**, Arbelaez C, Reichmann WM, Walls RM, Katz JN, Block BL, Dooley M, Hetland A, Kimmel S, Solomon J, Losina E. Revisiting expectations from rapid HIV tests in the emergency department. *Ann Intern Med*. 2008; 149:153-60.
51. **Walensky RP**, Freedberg KF, Weinstein MC. Monitoring of antiretroviral therapy in resource-limited settings. (letter) *Lancet*. 2008;372:288.
52. Ciaranello AL, Seage GR, Freedberg KA, Weinstein MC, Lockman S, **Walensky RP**. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. *AIDS*. 2008; 22:2359-2369.
53. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR, Sloan CE, Sax PE, **Walensky RP**. HIV pre-exposure (PrEP) in the United States: impact of lifetime infection risk, clinical outcomes, and cost-effectiveness. *Clin Infect Dis*. 2009; 48:806-15.
54. Ciaranello AL, **Walensky RP**, Sax PE, Chang Y, Freedberg KA, Weissman JS. Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents. *HIV Clin Trials*. 2009; 10:13-24.
55. Orrell C, **Walensky RP**, Losina E, Pitt J, Freedberg KA, Wood R. HIV-1 clade C resistance genotypes in naïve patients and after first virological failure in a large community ART programme. *Antivir Ther*. 2009; 14; 523-31.
56. Lyons MS, Lindsell CJ, Haukoos JS, Almond G, Brown J, Calderon Y, Couture E, Merchant RC, White DA, Rothman RE, Aldridge C, Almond G, Andrade G, Arbelaez C, Archinard TM, Aronin SI, Barrera S, Bateganya M, Bell-Merriam J, Bongiovanni B, Brady K, Branson B, Brosgart C, Brown J, Cadoff E, Calderon Y, Chaille-Arnold L, Cheng B, Chiang W, Copeland B, Cousar RL, Couture E, Czarnogorski M, Delgado K, Erbeling E, Feldman J, Garcia O, Gaydos CA, Glick N, Gripshover B, Haukoos J, Hayes A, Heffelfinger J, Herrera L, Hilley A, Holtgrave D, Hoots B, Hopkins E, Houry D, Howell D, Hsieh YH, Hutchinson AB, Jackson B, Jaker M, Jones K, Jung J, Kampe L, Kan V, Kass N, Kelen GD, Kroc K, Kurth A, Lampe MA, Leider J, Lemanski M, Lindsell CJ, Lyons M, McGovern S, Mercer S, Merchant R, Miertschin N, Miller J, Mitchell P, Nelson S, Onaga L, Paltiel D, Paul S, Pollack H, Raffanti S, Randall L, Rothman R, Sabreen A, Sankoff J, Sasso V, Saylor NB, Schechter E, Schechtman B, Schrantz S, Scribner A, Shahan J,

Skiest D, Spielberg F, Stennett IS, Sullivan P, Teahan C, Thompson S, Torres G, Totten V, Wagner K, **Walensky R**, Waxman M, Weddle A, White D, Widell T, Wilde JA, Wrenn K and Yonek J. Nomenclature and definitions for emergency department human immunodeficiency virus (HIV) testing: report from the 2007 conference of the National Emergency Department HIV Testing Consortium. *Acad Emerg Med*. Feb 2009;16(2):168-77. 10.1111/j.1553-2712.2008.00300.x.

57. Bassett IV, Wang B, Chetty S, Giddy J, Lu Z, Losina E, **Walensky RP**, Freedberg KA. Loss to care and death before antiretroviral therapy in Durban, South Africa. *J Acquir Immune Defic Syndr*. 2009; 51:130-134.
58. April MD, **Walensky RP**, Chang Y, et al. HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. *J Acquir Immune Defic Syndr*. 2009; 51:310-6.
59. Losina E, **Walensky RP**, Kessler CL, et al. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. *Arch Intern Med*. 2009; 169:1113-21; discussion 21-2.
60. Linas BP, Losina E, Rockwell A, **Walensky RP**, Cranston K, Freedberg KA. Improving outcomes in state AIDS drug assistance programs. *J Acquir Immune Defic Syndr*. 2009; 51:513-21.
61. **Walensky RP**. Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy. *Top HIV Med*. 2009; 17:130-4.
62. **Walensky RP**, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E. When to start antiretroviral therapy in resource-limited settings. *Ann Intern Med* 2009; 151:157-66.
63. Ciaranello AL, Chang Y, Margulis AV, Bernstein A, Bassett IV, Losina E, **Walensky RP**. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. *Clin Infect Dis*. 2009; 49(12):1915-27.
64. Losina E, Schackman BR, Sadownik SN, Gebo KA, **Walensky RP**, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and gender disparities in life expectancy losses among HIV-infected persons in the US: impact of risk behavior, late initiation and early discontinuation of antiretroviral therapy. *Clin Infect Dis*. 2009; 49:1570-8.
65. Arbelaez C, Block B, Losina E, Wright EA, Reichmann WM, Mikulinsky R, Solomon JD, Dooley MM, **Walensky RP**. Rapid HIV testing program implementation: lessons from the emergency department. *Int J Emerg Med*. 2009; 2(3):187–194.
66. Ganguli I, Bassett IV, Dong KL, **Walensky RP**. Home testing for HIV infection in resource-limited settings. *Curr HIV/AIDS Rep*. 2009; 6:217-23.

67. Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, **Walensky RP**, Messou E, Weinstein MC, Dabis F, Freedberg KA. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. *PLoS Med.* 2009; 6:e1000173.
68. Mimiaga MJ, Reichmann WM, Safren SA, Losina E, Arbelaez C, **Walensky RP**. Prevalence and correlates of clinically significant depressive symptoms in an urban hospital emergency department. *Prim Care Companion J Clin Psychiatry.* 2010; 12(2):e1-11.
69. Bender MA, Nagalingeswaran K, Mayer KH, Wang B, **Walensky RP**, Flanigan T, Schackman BR, Scott CA, Lu Z, Freedberg KA. The cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. *Clin Infect Dis.* 2010; 50:416–425.
70. **Walensky RP**, Kuritzkes DR. The impact of PEPfAR beyond HIV and why it remains essential. *Clin Infect Dis.* 2010; 50:272-5.
71. Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, Ross D, Katz JN, **Walensky RP**, Freedberg KA, Losina E. Who starts ART in Durban, South Africa?... Not everyone who should. *AIDS.* 2010; 24:S37–S44.
72. Williams-Roberts H, Chang Y, Losina E, Freedberg KA, **Walensky RP**. Frequent HIV testing among participants of a routine HIV testing program. *Virulence.* 2010; 1(2):68-71.
73. Yazdanpanah Y, Wolf LL, Anglaret X, Gabillard D, **Walensky RP**, Moh R, Danel CH, Sloan CE, Losina E, Freedberg KA. CD4-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. *Antivir Ther.* 2010; 15(3):351-61.
74. Bassett IV, **Walensky RP**. Integrating HIV screening into routine health care in resource limited-settings. *Clin Infect Dis.* 2010;50 Suppl 3:S77-84.
75. Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, Messou E, Cotich KL, **Walensky RP**, Freedberg KA. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. *J Acquir Immune Defic Syndr.* 2010; 54(3):258-68.
76. Reichmann WR, Losina E, Seage GR, Arbelaez C, Safren S, Katz JN, Hetland A, **Walensky RP**. Does modality of survey administration impact data quality: audio computer assisted self interview (ACASI) vs. self-administration pen and paper? *PLoS One.* 2010; 5:e8728.
77. Losina EL, Bassett IV, Giddy J, Chetty S, Regan S, **Walensky RP**, Ross D, Scott CA, Uhler LA, Katz JN, Holst H, Freedberg KA. The ART of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa *PLoS One.* 2010; 5:e9538.
78. **Walensky RP**, Ciaranello AC, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in Sub-Saharan Africa: a review of the current literature. *Clin Infect Dis.* 2010; 51(1):85-92. Review. PMC2880656.

79. Martin EG, Paltiel AD, **Walensky RP**, and Schackman BR. Expanded HIV screening in the US: what it will cost government discretionary and entitlement programs? A budget impact analysis. *Value Health*. 2010; 8:893-902.
80. **Walensky RP**, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, Seage GR, Freedberg KA. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. *Clin Infect Dis*. 2010; 51(4):392-400.
81. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, **Walensky RP**, Freedberg KA. Intensive tuberculosis screening for HIV-infected patients starting ART in Durban, South Africa. *Clin Infect Dis*. 2010; 51(7):823-9.
82. Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, Stoler AW, Zhigang L, **Walensky RP**, Flanigan TP, Bender MA, Freedberg KA, Swaminathan S. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. *PLoS One*. 2010; 5(9):pii e12747.
83. Yazdanpanah Y, Sloan CE, Charlois-Ou C, LeVu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, **Walensky RP**, Freedberg KA, Paltiel AD. Routine HIV screening in France: clinical impact and cost-effectiveness. *PLoS One*. 2010; 5(10):e13132.
84. **Walensky RP**, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler A, Freedberg KA. Scaling up the 2010 WHO HIV treatment guidelines in resource-limited settings: a model-based analysis. *PLoS Med*. 2010; 7(12):e1000382.
85. Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, **Walensky RP**, Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on healthcare utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. *J Viral Hepat*. 2011; 18:506-512.
86. Bassett IV, Chetty S, Giddy J, Reddy S, Bishop K, Lu Z, Losina E, Freedberg KA, **Walensky RP**. Screening for acute HIV infection in South Africa: finding acute and chronic disease. *HIV Med*. 2011; 12(1):46-53.
87. **Walensky RP**, Reichmann WM, Arbealez C, Wright E, Katz JN, Seage GR, Safren SA, Hare A, Novais A, Losina E. Counselor- vs. provider-based HIV screening in the emergency department: results from the Universal Screening for HIV-infection in the Emergency Room (USHER) randomized controlled trial. *Ann Emerg Med*. 2011; 58:126-132.
88. Donnell-Fink L, Reichmann WM, Arbelaez C, Case AL, Katz JN, Losina E, **Walensky RP**. Patient satisfaction with rapid HIV testing in the emergency department. *Ann Emerg Med*. 2011; 58:49-52.
89. Hsu H, **Walensky RP**. Cost-effectiveness analysis and HIV screening: the emergency medicine perspective. *Ann Emerg Med*. 2011; 58:145-150.

90. Hsu HE, Rydzak CE, Cotich KL, Wang B, Sax PE, Losina E, Freedberg KA, Goldie SJ, Lu Z, **Walensky RP**. Quantifying the risks and benefits of efavirenz use in HIV-infected women of child-bearing age in the United States. *HIV Med*. 2011; 12:97-108.
91. **Walensky RP**, Wood R, Fofana MO, Martinson N, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. *J Acquir Immune Defic Syndr*. 2011; 56(1):26-35.
92. Pisculli ML, Reichmann WM, Losina E, Donnell-Fink LA, Arbelaez C, Katz JN, **Walensky RP**. Factors associated with refusal of rapid HIV testing in an emergency department. *AIDS Behav*. 2011; 15:734-42.
93. Wang B, Losina E, Stark R, Munro A, **Walensky RP**, Wilke M, Martin D, Lu Z, Freedberg KA, Wood R. Lost to follow-up in a community clinic in South Africa: role of sex, pregnancy, and CD4 count. *S Afr Med J*. 2011; 101:253-257.
94. Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, **Walensky RP**. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. *AIDS*. 2011; 25(4):479-492.
95. Losina E, **Walensky RP**, Holt H, Gerlovin, Reichmann WM, Kessler CL, Solomon DH, Jordan JM, Hunter DJ, Suter LG, Paltiel AD, Katz JN. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. *Ann Intern Med*. 2011; 154(4):217-26.
96. April MD, Chiosi JJ, Paltiel AD, Sax PE, **Walensky RP**. Projected survival gains from revising state laws requiring written opt-in consent. *J Gen Intern Med*. 2011; 26:661-7.
97. Ciaranello AC, Park JE, Ramirez-Avila L, Freedberg KA, **Walensky RP**, Leroy V. Early infant HIV-1 diagnosis programs in resource limited settings: opportunities for improved outcomes and more cost-effective interventions. *BMC Med*. 2011; 9(1):59.
98. Ciaranello AC, Perez F, Maruva M, Chu J, Englesmann B, Keatinge J, **Walensky RP**, Mushavi A, Mugwagwa R, Dabis F, Freedberg KA. WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. *PLoS One*. 2011; 6(6):e20224.
99. **Walensky RP** and Bassett IV. HIV self-testing and the missing linkage. *PLoS Med*. 2011; 8(10):e1001101.
100. **Walensky RP**, Morris BL, Reichmann WM, Paltiel AD, Arbelaez C, Donnell-Fink L, Katz JN, Losina E. Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. *PLoS One*. 2011; 6(10):e25575.
101. Kerry VB, Ndung-u T, **Walensky RP**, Lee PT, Kyanja FIB, Bangsberg DR. Managing the demand for global health education. *PLoS Med*. 2011; 8(11):e1001118.

102. Reichmann WM, **Walensky RP**, Case AL, Novais A, Arbelaez C, Katz JN, Losina E. Estimation of the prevalence of undiagnosed and diagnosed HIV in an urban emergency department. *PLoS One*. 2011; 6(11):e27701.
103. Arbelaez C, Wright EA, Losina E, Millen JC, Dooley MM, Reichmann W, Mikulinsky R, **Walensky RP**. Emergency provider attitudes and barriers to universal HIV testing in the emergency department. *J Em Med*. 2012; 42(1):7-14.
104. Sloan CE, Campenois, Choisy P, Losina E, **Walensky RP**, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. *AIDS*. 2012; 26(1):45-56.
105. Tucker JD, **Walensky RP**, Yang LG, Yang B, Bangsberg DR, Chen XS and Cohen MS. Expanding provider-initiated HIV testing at STI clinics in China. *AIDS Care*. 2012;24(10):1316-9. 10.1080/09540121.2012.661835.
106. Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler R, Haynes L, Tross S, Kyle T, Gallup D, Kosinski AS, Douaihy A, Schackman BR, Das M, Lindblad R, Erickson S, Korthuis T, Sorensen J, Szapocznik J, **Walensky RP**, Branson B, Colfax, GN. Implementing rapid HIV testing with or without risk-reduction counseling in substance abuse treatment centers: results of a randomized trial. *Am J Public Health*. 2012; 102(6):1160-1167.
107. Ciaranello AL, Perez F, Keating J, Park JE, Engelsmann B, Matthews M, **Walensky RP**, Dabis F, Chu J, Rusibamayila A, Mushavi A, Freedberg KA. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child transmission in Zimbabwe. *PLoS Med*. 2012; 9(1):e1001156.
108. O'Hagan JJ, Hernan MA, **Walensky RP**, Lipsitch M. Apparent declining efficacy in randomized trials: examples of the RV144 HIV vaccine and CAPRISA 004 microbicide trials. *AIDS*. 2012; 26(2):123-6.
109. Andrews JR, Noubary F, **Walensky RP**, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with *M. tuberculosis*. *Clin Infect Dis*. 2012; 54(6):784-91.
110. Bassett IV, Chetty S, Wang B, Mazibuko M, Giddy J, Lu Z, **Walensky RP**, Freedberg KA, Losina E. Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. *J Acquir Immune Defic Syndr*. 2012; 59(1):25-30.
111. Ramirez-Avila L, Regan S, Giddy J, Chetty S, Ross D, Katz JN, Freedberg KA, **Walensky RP**, Losina E, Bassett IV. Depressive symptoms and their impact on health-seeking behaviors in newly-diagnosed HIV-infected patients in Durban, South Africa. *AIDS Behav*. 2012; 16(8):2226-35.
112. Ouattara E, Anglaret X, Wong AY, Chu J, Hsu HE, Danel C, Eholié S, Moh R, Gabillard D, **Walensky RP**, Freedberg KA. Projecting the clinical benefits and risks of using efavirenz-containing ART regimens in women of childbearing age in sub-Saharan Africa. *AIDS*. 2012; 26(5):625-34.

113. **Walensky RP**, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina El, Mayer KH, Seage GR, Paltiel AD. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. *Clin Infect Dis*. 2012; 54(10):1504-13.
114. Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, **Walensky RP**. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. *AIDS*. 2012; 26(9):1083-1093.
115. Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, Horsburgh CR, Losina E, Freedberg KA, **Walensky RP**. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy in South Africa: a model-based analysis. *AIDS*. 2012; 26(8):987-995.
116. Andrews JR, Wood R, Bekker LG, Middelkoop L, **Walensky RP**. Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care. *J Infect Dis*. 2012; 206(4):543-51.
117. Shenoy ES, **Walensky RP**, Lee H, Orcutt B, Hooper DC. Resource burden associated with contact precautions for methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococcus: the patient access managers' perspective. *Infect Control Hosp Epidemiol*. 2012; 33(8):849-52.
118. Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, Scott CA, Mayer KH, Freedberg KA, **Walensky RP**. The cost-effectiveness of TB preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. *PLoS One*. 2012; 7(4):e36001.
119. Shenoy ES, Hsu HE, Noubary F, Hooper DC, **Walensky RP**. National survey of infection preventionists: policies for discontinuation of contact precautions for methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococcus. *Infect Control Hosp Epidemiol*. 2012; 33(12).
120. Donnell-Fink L, Arbelaez C, Collins JE, Novais A, Case A, Pisculli ML, Reichmann WM, Katz J, Losina E, **Walensky RP**. Acceptability of fingerstick vs. oral fluid rapid HIV testing: results from the Universal Screening for HIV-infection in the Emergency Room (USHER-Phase II) randomized controlled trial. *J Acquir Immune Defic Syndr*. 2012; 61(5):588-92.
121. Hom JK, Wang B, Chetty S, Giddy J, Mazibuko M, Allen J, **Walensky RP**, Losina E, Freedberg KA and Bassett IV. Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa. *PLoS One*. 2012;7(8):e43281. 10.1371/journal.pone.0043281.
122. Paltiel AD, **Walensky RP**. Home HIV testing: good news but not a game changer. *Ann Intern Med*. 2012; 157(1):744-6.
123. Ramirez-Avila L, Nixon K, Noubary F, Giddy J, Losina E, **Walensky RP**, Bassett IV. Routine HIV testing in adolescents and young adults presenting to an outpatient clinic in Durban, South Africa. *PLoS One*. 2012; 7(9):e45507.

124. Anglaret X, Scott C, **Walensky RP**, Ouattera E, Losina E, Moh R, Becker J, Uhler L, Danel C, Messou E, Eholié S, Freedberg KA. Could early antiretroviral therapy entail more risks than benefits in Sub-Saharan African HIV-infected adults? A model-based analysis. *Antivir Ther.* 2013; 18(1):45-55.
125. Ciaranello AL, Perez F, Engelsmann B, **Walensky RP**, Mushavi A, Rusibamayila A, Keatinge J, Park JE, Maruva M, Cerda R, Wood R, Dabis F, Freedberg KA. The cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. *Clin Infect Dis.* 2013; 56(3):430-46.
126. Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Haynes LF, Paltiel AD, **Walensky RP**. The cost-effectiveness of rapid HIV testing in substances abuse: results of a randomized trial. *Drug Alcohol Depend.* 2013; 128(1-2):90-7.
127. Levison JH, Wood R, Scott CA, Ciaranello AL, Martinson NA, Rusu C, Losina E, Freedberg KA, **Walensky RP**. The clinical and economic impact of genotype testing at first-line antiretroviral therapy: failure for HIV-infected patients in South Africa. *Clin Infect Dis.* 2013; 56(4):587-97.
128. Bogart LM, Chetty S, Giddy J, Sypek A, Sticklor L, **Walensky RP**, Losina E, Katz JN, Bassett IV. Barriers to care among people living with HIV in South Africa: contrasts between patient and healthcare provider perspectives. *AIDS Care.* 2013; 25(7):843–853.
129. **Walensky RP**, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. *Ann Intern Med.* 2013; 158(2):84-92.
130. Ganguli I, Collins JE, Reichmann WM, Losina E, Katz JN, Arbelaez C, Donnell-Fink LA, **Walensky RP**. Missed opportunities: refusal to confirm reactive rapid HIV tests in the emergency department. *PLoS One.* 2013; 8(1):e53408.
131. Drain PK, Losina E, Parker G, Giddy J, Ross D, Katz JN, Coleman SM, Bogart LM, Freedberg KA, **Walensky RP**, Bassett IV. Risk factors for late-stage HIV disease presentation at initial HIV diagnosis in Durban, South Africa. *PLoS One.* 2013; 8(1):e55305.
132. Losina E, Daigle ME, Reichmann WM, Suter LG, Hunter DJ, Solomon DH, **Walensky RP**, Jordan JM, Burbine SA, Paltiel AD, Katz JN. Disease modifying drugs for knee osteoarthritis: can they be cost-effective? *Osteoarthritis Cartilage.* 2013; 21(5):655-67.
133. Shenoy ES, Kim J, Rosenberg ES, Cotter JA, Lee H, **Walensky RP**, Hooper DC. Discontinuation of contact precautions for methicillin-resistant staphylococcus aureus: a randomized controlled trial comparing passive and active screening with culture and polymerase chain reaction. *Clin Infect Dis.* 2013; 57(2):176-84.
134. Regan S, Losina E, Chetty S, Giddy J, **Walensky RP**, Ross D, Holst H, Katz JN, Freedberg KA, Bassett IV. Factors associated with self-reported repeat HIV testing after a negative result in Durban, South Africa. *PLoS One.* 2013; 8(4):e62362.

135. Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, Swaminathan S, Flanigan TP, **Walensky RP**, Freedberg KA. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. *PLoS One*. 2013; 8(5):e64604.
136. Hyle EP, Wood BR, Backman ES, Noubary F, Hwang J, Lu Z, Losina E, **Walensky RP**, and RT Gandhi. High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy. *J Acquir Immune Defic Syndr*. 2013; 63(5):602-8.
137. Ramirez-Avila L, Noubary F, Pansegrouw D, Sithole S, Giddy J, Losina E, **Walensky RP**, Bassett IV. The acceptability and feasibility of routine pediatric HIV testing in an outpatient clinic in Durban, South Africa. *Pediatr Infect Dis J*. 2013; 32(12):1348-53.
138. **Walensky RP**. Combination HIV prevention: the value and interpretation of mathematical models. *Current HIV/AIDS Reports*. 2013; 10(3):195-8.
139. Kerry VB, **Walensky RP**, Tsai AC, Bergmark R, Bergmar B, Rouse C, Bangsberg DR. US medical specialty global health training and the global burden of disease. *J Glob Health*. 2013; 3(2):020406.
140. Bassett IV, Giddy J, Chaisson CE, Ross D, Bogart LM, Coleman SM, Govender T, Robine M, Erlwanger A, Freedberg KA, Katz JN, **Walensky RP**, Losina E. A randomized trial to optimize HIV/TB care in South Africa: design of the Sizanani Trial. *BMC Infect Dis*. 2013, 13:390.
141. Govindasamy D, Kranzer K, van Schaik N, Noubary F, Wood R, **Walensky RP**, Freedberg, KA, Bassett IV, Bekker GL. Linkage to HIV, TB and non-communicable disease care from a mobile testing unit in Cape Town, South Africa. *PLoS One*. 2013; 8:e80017.
142. **Walensky RP**, Ross EL, Kumarasamy N, Wood R, Noubary F, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Want L, McCauley M, Gamble T, Seage GR, Cohen MS, Freedberg KA. The cost-effectiveness of HIV treatment as prevention in serodiscordant couples. *N Engl J Med*. 2013; 369(18):1715–1725.
143. Ciaranello AL, Morris BL, **Walensky RP**, Weinstein MC, Ayaya S, Doherty K, Leroy V, Hou T, Desmonde S, Lu Z, Noubary F, Patel K, Ramirez-Avila L, Losina E, Seage GR, Freedberg KA. Validation and calibration of a computer simulation model of pediatric HIV infection. *PLoS One*, 2013; 8(12):383389.
144. Yazdanpanah Y, Perelman J, Dileonzo MA, Alves J, Barros H, Mateus C, Pereira J, Mansinho K, Robine M, Park J, Ross EL, Losina E, **Walensky RP**, Noubary F, Freedberg KA, Paltiel AD. Routine HIV screening in Portugal: clinical impact and cost-effectiveness. *PLoS One*. 2013; 8(12):e84173.
145. Hyle EP, Sax PE, **Walensky RP**. Potential savings by reduced CD4 monitoring in stable HIV patients on antiretrovirals. *JAMA Inter Med*. 2013; 173(18):1746-8.
146. Andrews JR, Lawn SD, Dowdy DW, **Walensky RP**. Challenges in evaluating the cost-effectiveness of new diagnostics for HIV-associated tuberculosis. *Clin Infect Dis*. 2013;

57(7):1021-6.

147. Yazdanpanah Y, Walensky RP, Rozenbaum W, Yeni P and Paltiel AD. What is a modest public health impact? *Arch Intern Med.* Mar 26 2012;172(6):521-2; author reply 522-3. 10.1001/archinternmed.2011.1876.
148. Hung KJ, Tsa AC, Johnson TRB, **Walensky RP**, Bangsberg BR, Kerry VB. Global health training in US obstetrics and gynecology residency programs. *Obstet Gynecol.* 2013; 122(5):1101-9.
149. McCormick AW, Abuelezam NN, Rhode ER, Hou T, **Walensky RP**, Pei PP, Becker JE, DiLorenzo MA, Losina E, Freedberg KA, Lipsitch M, Seage GR. Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: applied in South Africa. *PLoS One.* 2014; 9(5):e98272.
150. Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, Noubary F, Paltiel AD, Wood R, **Walensky RP**, Losina E, Bekker LG, Freedberg KA. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. *PLoS One.* 2014; 9(1):e85197.
151. Shenoy ES, Paras ML, Noubary F, **Walensky RP**, Hooper D. Natural history of colonization with methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE): a systematic review. *BMC Infect Dis.* 2014; 14:177.
152. April MD, Wood R, Berkowitz B, Paltiel AD, Anglaret X, Losina E, Freedberg KA, **Walensky RP**. The survival benefits of antiretroviral therapy in South Africa. *J Infect Dis.* 2014; 209(4):491-499.
153. Shenoy ES, Noubary F, Kim JY, Rosenberg E, Cotter J, Lee H, **Walensky RP**, Hooper D. Concordance of PCR and culture from nasal swabs for MRSA in setting of concurrent anti-staphylococcal antibiotics. *J Clin Microbiol.* 2014; 52(4):1235-7.
154. Tsai AC, Fricchione GL, **Walensky RP**, Ng C, Bangsberg DR, Kerry VB. Global health training in US graduate psychiatric education. *Acad Psychiatry.* 2014; 38(4):426-32.
155. Ciaranello AL, Leroy V, Rusibamayila A, Freedberg KA, Shapiro R, Engelsmann B, Lockman S, Kelly KA, Dabis F, **Walensky RP**. Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival. *AIDS.* 2014; 28 Suppl 3:S287-99.
156. Marrazzo JM, del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, Montaner JSG, Wheeler DP, Grant RM, Grinsztejn B, Kumarasamy N, Shoptaw SJ, **Walensky RP**, Dabis F, Sugarman J, Benson CA. Combination HIV prevention in clinical care settings in 2014: recommendations of an international antiviral society-USA panel. *JAMA.* 2014; 312(4):390-409.
157. Hyle EP, Jani IV, Lehe J, Su AE, Wood R, Quevedo J, Losina E, Bassett IV, Pei PP, Paltiel AD, Resch S, Freedberg KA, Peter T, **Walensky RP**. The clinical and economic impact of point-of-care CD4 testing in Mozambique and other resource-limited settings: a cost-effectiveness analysis. *PLoS Med.* 2014; 11(9):e1001725.

158. O’Laughlin KN, Kasozi J, **Walensky RP**, Parker RA, Faustin ZM, Doraiswamy S, Owino CO, Bassett IV. Clinic-based routine voluntary HIV testing in a refugee settlement in Uganda. *J Acquir Immune Defic Syndr*. 2014; 67(4):409-13.
159. Cloete C, Regan S, Giddy J, Govender T, Erlwanger A, Gaynes MR, Freedberg KA, Katz JN, **Walensky RP**, Losina E, Bassett IV. The linkage outcomes of a large-scale, rapid transfer of HIV-infected patients from hospital-based to community-based clinics in South Africa. *Open Forum Infect Dis*. 2014; 1(2):ofu058.
160. Wood R, Morrow C, Ginsberg S, Piccoli E, Kalil D, Sassi A, **Walensky RP**, Andrews JR. Quantification of shared air: a social and environmental determinant of airborne disease transmission. *PLoS One*. 2014; 9(9):e106622.
161. Ross EL, Tanser F, Pei PP, Newell ML, Losina E, Thiebaut R, Weinstein MC, Freedberg KA, Anglaret X, Scott CA, Dabis F, **Walensky RP**. The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials. *HIV Clin Trials*. 2014; 15(5):185-198.
162. Cardoso SW, Luz PM, Velasque L, Torre T, Coelho L, Freedberg KA, Veloso VG, **Walensky RP**, Grinsztejn B. Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil. *AIDS Res Ther*. 2014; 11:29.
163. Andrews JR, Morrow C, **Walensky RP**, Wood R. Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African township. *J Infect Dis*. 2014; 210(4):597-603.
164. Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, **Walensky RP**, Danel C, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d’Ivoire. *J Acquir Immune Defic Syndr*. 2014; 66(3):294-302.
165. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, **Walensky RP**, Freedberg KA, Bassett IV. Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly diagnosed HIV-infected adults: a prospective, clinic-based study. *BMC Infect Dis*. 2014; 14:110.
166. Bassett IV, Regan S, Luthuli P, Mbonambi H, Bearnot B, Pendleton A, Robine M, Mukuvisi D, Thulare H, **Walensky RP**, Freedberg KA, Losina E, Mhlongo B. Linkage to care following community-based mobile HIV testing compared with clinic-based testing in Umlazi Township, Durban, South Africa. *HIV Med*. 2014; 15(6):367-72.
167. Sax PE, Sypek A, Berkowitz BK, Morris BL, Losina E, Paltiel AD, Kelly KA, Seage GR, **Walensky RP**, Weinstein MC, Eron J, Freedberg KA. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? *PLoS One*. 2014; 9(11):e113031.

168. Ramirez-Avia L, Regan S, Chetty S, Giddy J, Ross D, Katz JN, Freedberg KA, Losina E, **Walensky RP**, Bassett IV. HIV testing rates, prevalence, and knowledge among outpatients in Durban, South Africa: time trends over four years. *Intl J STD AIDS*. 2015; 26(10):704-9.
169. Losina E, Paltiel AD, Weinstein AM, Yelin E, Hunter DJ, Chen SP, Klara K, Suter LG, Solomon DH, Burbine SA, **Walensky RP**, Katz JN. Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indication for total knee arthroplasty. *Arthritis Care Res (Hoboken)*. 2015; 67(2):203-15.
170. Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, **Walensky RP**, Losina E, Nakamura YM, Giouard MP, Sax PE, Struchiner CJ, Paltiel AD. The cost-effectiveness of genotype testing for primary resistance in Brazil. *J Acquir Immune Defic Syndr*. 2015; 68(2):152-161.
171. Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, **Walensky RP**, Freedberg KA, Losina E. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. *Clin Infect Dis*. 2015; 60(7):1102-10.
172. **Walensky RP**, Auerbach JD. Focusing National Institutes of Health HIV/AIDS research for maximum population impact. *Clin Infect Dis*. 2015; 60(6):937-40.
173. Ciaranello AL, Doherty K, Penazzato M, Lindsey JC, Harrison L, Kelly K, **Walensky RP**, Essajee S, Hou T, Losina EL, Muhe L, Wools-Kaloustian K, Ayaya S, Weinstein MC, Palumbo P, Freedberg KA. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than three years of age. *AIDS*. 2015; 29(10):1247-59.
174. Schackman BR, Fleishman JA, Su AE, Berkowitz BK, Moore RM, **Walensky RP**, Becker JE, Voss C, Paltiel AD, Weinstein MC, Freedberg KA, Gebo KA, Losina E. The lifetime medical cost savings from preventing HIV in the United States. *Med Care*. 2015; 53(4):293-301.
175. Ciaranello AL, Myer L, Kelly K, Christensen S, Daskilewicz K, Doherty K, Bekker LG, Hou T, Wood R, Wools-Kaloustian K, Freedberg KA, **Walensky RP**. Point-of-care CD4 testing to inform selection of antiretroviral medications in South African antenatal clinics: a cost-effectiveness analysis. *PLoS One*. 2015; 10(3):e0117751.
176. Bassett IV, Regan S, Mbonambi H, Blossom J, Bogan S, Bearnot B, Robine M, **Walensky RP**, Freedberg KA, Thulare H, Losine E. Finding HIV in hard to reach populations: mobile HIV testing and geospatial mapping in Umlazi Township, Durban, South Africa. *AIDS Behav*. 2015; 2015; 19(10):1888-95.
177. Blumenthal KG, Youngster I, Rabideau DJ, Parker RA, Manning KS, **Walensky RP**, Nelson SB. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. *J Allergy Clin Immunol*. 2015; pii: S0091-6749(15)00541-2.
178. Blumenthal KG, Parker RA, Shenoy ES, **Walensky RP**. Improving clinical outcomes in patients with methicillin-sensitive *Staphylococcus aureus* bacteremia and reported penicillin allergy. *Clin Infect Dis*. 2015; 61(5):741-9.

179. **Walensky RP**, Hirsch MS. Age-old questions: when to start antiretroviral therapy and in whom? *Clin Infect Dis*. 2015; 61(7):1196-8.
180. Paras ML, Shenoy ES, Hsu HE, **Walensky RP**, Hooper DC. Housestaff knowledge related to urinary catheter utilization and catheter-associated urinary tract infections. *Infect Control Hosp Epidemiol*. 2015; 00(0):1-3.
181. Hsu HE, Shenoy ES, Kelbaugh D, Ware W, Lee H, Zakrofsky P, Hooper DC, **Walensky RP**. An electronic surveillance tool for catheter-associated urinary tract infection in intensive care units. *Am J Infect Control*. 2015;43(6):592-9.
182. Shenoy ES, Lee H, Cotter JA, Ware W, Kelbaugh D, Weil E, **Walensky RP**, Hooper DC. Impact of rapid screening for discontinuation of MRSA contact precautions. *Am J Infect Control*. 2016; 44(2):215-21.
183. Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, **Walensky RP**. Prioritizing HIV comparative effectiveness trials based on value of information: generic vs. brand-name ART in the US. *HIV Clin Trials*. 2015; 16(6):207-18.
184. Freedberg KA, Possas C, Deeks S, Ross AL, Rosettie KL, Di Mascio M, Collins C, **Walensky RP**, Yazdanpanah Y. The HIV cure research agenda: the role of mathematical modeling and cost-effectiveness analysis. *J Virus Erad*. 2015; 1:245-249.
185. Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, **Walensky RP**. The cost-effectiveness and budget impact of two-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. *Clin Infect Dis*. 2015; 62(6):784-91.
186. **Walensky RP**, Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC, Horstman NK, Freedberg KA, Paltiel AD. Potential clinical and economic value of long-acting pre-exposure prophylaxis for HIV Infection in high-risk South African women. *J Infect Dis*. 2015; 213(10):1523-31.
187. **Walensky RP**, Horn TH, Paltiel AD. The epi-TAF of TDF? *Clin Infect Dis*. 2015; 62(7):915-8.
188. Jacobsen MM, **Walensky RP**. Modeling and cost-effectiveness in HIV prevention. *Curr HIV/AIDS Rep*. 2016; 13(1):64-75.
189. Reddy KP, Bajwa EK, Parker RA, Onderdonk AB, **Walensky RP**. Relationship between upper respiratory tract influenza test result and clinical outcomes among critically ill influenza patients. *Open Forum Infect Dis*. 2016; 3(1):ofw023.
190. Shenoy ES, Lee H, Hou T, Ware W, Ryan E, Hooper DC, **Walensky RP**. The impact of methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE) flags on hospital operations. *Infect Control Hosp Epidemiol*. 2016; 37(7):782-90.

191. Luz PM, Girouard MP, Grinsztejn B, Freedberg KA, Veloso VG, Losina E, Struchiner CJ, Maclean RL, Parker RA, Paltiel AD, **Walensky RP**. Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. *J Int AIDS Soc*. 2016; 19(1):20623.
192. Ouattara EN, Robine MR, Eholié S, MacLean RL, Moh R, Losina E, Gabillard D, Paltiel AD, Danel C, **Walensky RP**, Anglaret X, Freedberg KA. Laboratory monitoring of antiretroviral therapy for HIV infection: cost-effectiveness and budget impact of current and novel strategies. *Clin Infect Dis*. 2016; 62(11):1454-62.
193. Bassett IV, Coleman SM, Giddy J, Bogart LM, Chaisson CE, Ross D, Jacobsen MM, Robine M, Govender T, Freedberg KA, Katz JN, **Walensky RP**, Losina E. Sizanani: a randomized trial of health system navigators to improve linkage to HIV and TB care in South Africa. *J Acquir Immune Defic Syndr*. 2016; 73(2):154-60.
194. **Walensky RP**, Borre ED, Bekker LG, Resch SC, Hyle EP, Wood R, Weinstein MC, Ciaranello AL, Freedberg KA, Paltiel AD. The anticipated clinical and economic impact of 90-90-90 in South Africa. *Ann Intern Med*. 2016; 165(5):325-33.
195. Blumenthal KG, Shenoy ES, Huang M, Kuhlen JL, Ware WA, Parker RA, **Walensky RP**. The impact of reporting prior penicillin allergy on the treatment of methicillin-sensitive *Staphylococcus aureus* bacteremia. *PLoS One*. 2016; 11(7):e0159406.
196. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen EA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, Van Lunzen J, Walensky R, Wilson I, Zack J and International ASTaCWG. International AIDS Society global scientific strategy: Towards an HIV cure 2016. *Nature Medicine*. 2016;22(8):839-850. 10.1038/nm.4108.
197. Reddy KP, Parker RA, Losina E, Baggett TP, Paltiel AD, Rigotti NA, Weinstein MC, Freedberg KA, **Walensky RP**. The impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. *J Infect Dis*. 2016; 214:1672-81.
198. O'Laughlin KN, Rabideau DJ, Kasozi J, Parker RA, Bustamante ND, Faustin ZM, Greenwald KE, **Walensky RP**, Bassett IV: Predictors of HIV infection: a prospective HIV screening study in a Ugandan refugee settlement. *BMC Infect Dis*. 2016; 16:695
199. Gupta-Wright A, Fielding KL, van Oosterhout JJ, Wilson DK, Corbett EL, Flach C, Reddy KP, **Walensky RP**, Peters JA, Alufandika-Moyo M, Lawn SD. Rapid urine-based screening for tuberculosis to reduce AIDS-related mortality in hospitalized patients in Africa (the STAMP trial): study protocol for a randomised controlled trial. *BMC Infect Dis*. 2016; 16:501. Erratum in: *BMC Infect Dis*. 2016; 16:604.
200. Francke JA, Penazzato M, Hou T, Abrams EJ, MacLean RL, Myer L, **Walensky RP**, Leroy V, Weinstein MC, Parker RA, Freedberg KA, Ciaranello A. Clinical impact and cost-effectiveness of

- early infant HIV diagnosis in South Africa: test timing and frequency. *J Infect Dis.* 2016; 214:1319-28.
201. **Walensky RP.** Investing in people who inject drugs: a PrEPonderance of opportunities. *Ann Intern Med.* 2016; 165(1): 63-64.
 202. Ramirez-Avila L, Regan S, Cloete C, Crankshaw T, Rabideau DJ, Freedberg KA, Parker RA, **Walensky RP**, Losina E, Bassett IV. Adolescent linkage to care after a large-scale transfer from a hospital-based HIV clinic to the public sector in South Africa. *Pediatric Infect Dis J.* 2017; 36(3):311-313.
 203. O’Laughlin KN, Kasozi J, Rabideau DJ, Parker RA, Mulogo E, Faustin ZM, Greenwald KE, Doraiswamy S, **Walensky RP**, Bassett IV. The cascade of HIV care among refugees and nationals in Nakivale refugee settlement in Uganda. *HIV Med.* 2017; 18(7): 513-518.
 204. Sacks CA, Goldstein RH, **Walensky RP.** Rethinking the ban – the US blood supply and men who have sex with men. *N Engl J Med.* 2017; 376(15):1486-7.
 205. Bassett IV, Coleman SM, Giddy J, Bogart LM, Chaisson CE, Ross D, Flash MJE, Govender T, **Walensky RP**, Freedberg KA, Losina E. Barriers to care and 1-year mortality among newly-diagnosed HIV-infected people in Durban, South Africa. *J Acquir Immune Defic Syndr.* 2017; 74(4):432-438.
 206. Blumenthal KG, Wickner PG, Hurwitz S, Pricco N, Nee AN, Laskowski K, Shenoy ES, **Walensky RP.** Tackling inpatient penicillin allergies: tools for antimicrobial stewardship. *J Allergy Clin Immunol.* 2017; 140(1): 154-161.e6.
 207. **Walensky RP**, del Rio C, Armstrong WS. Charting the future of infectious disease: anticipating and addressing the supply and demand mismatch. *Clin Infect Dis.* 2017; 64(10):1299-1301.
 208. Shenoy ES, Lee H, Ryan EE, Hou T, **Walensky RP**, Ware W, Hooper DC. A discrete event simulation model of patient flow in a general hospital incorporating infection control policy for methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE). *Med Decis Making.* 2017; 272989X17713474. PubMed PMID: 28662601.
 209. Hyle EP, Rao SR, Jentes ES, Fiebelkorn AP, Hagmann SHF, Walker AT, Sotir MJ, **Walensky RP**, Ryan ET, LaRocque RC. Missed opportunities for MMR vaccination among departing U.S. adult travelers receiving pretravel health consultations. *Ann Intern Med.* 2017; 167(2): 77-84.
 210. Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, **Walensky RP.** Setting performance standards for a cost-effective HIV cure strategy in South Africa. *Open Forum Infect Dis.* 2017; 4(2): ofx081.
 211. **Walensky RP.** Please pass the peanut butter. *J Infect Dis.* 2017; 216(5):S613-S614.
 212. Koullias YK, Sax PE, Fields NF, **Walensky RP**, Hyle EP. Should we be testing for baseline integrase resistance in patients newly diagnosed with HIV? *Clin Infect Dis.* 2017; 65(8):1274-1281.

213. Losina E, Hyle EP, Borre E, Linas BP, Sax PE, Weinstein MC, Rusu C, Ciaranello AL, **Walensky RP**, Freedberg KA. Projecting 10-yr, 20-yr and lifetime risks of cardiovascular disease in HIV-infected individuals in the US. *Clin Infect Dis*. 2017; 65(8):1266-1271.
214. Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, **Walensky RP**. The clinical and economic impact of attaining the National HIV/AIDS Strategy treatment targets in the US. *J Infect Dis*. 2017; 216(7):798-807.
215. Hyle EP, Jani IV, Rosettie KL, Wood R, Osher B, Resch S, Pei PP, Maggiore P, Freedberg KA, Peter T, Parker RA, **Walensky RP**. The value of point-of-care CD4 and laboratory viral load in tailoring ART monitoring strategies to resource limitations. *AIDS*. 2017; 31(15):2135-2145.
216. Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, Paltiel AD, Losina E, Weinstein MC, Freedberg KA, **Walensky RP**. Lung cancer mortality among people living with HIV in the United States: impact of smoking and smoking cessation. *JAMA Intern Med*. 2017; 177(11):1613-1621.
217. Rabideau DJ, Pei PP, **Walensky RP**, Zheng A, Parker RA. Implementing generalized additive models to estimate the expected value of sample information in microsimulation model; results of three case studies. *Med Decision Making*. 2017; 38(2):189-199.
218. Blumenthal KG, Li Y, Banerji A, Yun BJ, Long AA, **Walensky RP**. The cost of penicillin allergy evaluation. *J Allergy Clin Immunol Pract*. 2018; 6(3):1019-1027.e2.
219. **Walensky RP**, Borre ED, Bekker LG, Hyle EP, Gonsalves G, Wood R, Eholié S, Weinstein MC, Freedberg KA, Paltiel AD. Do less harm: evaluating HIV programmatic alternatives in response to cutbacks in foreign aid. *Ann Intern Med*. 2017; 167(9):618-629.
220. Neilan AM, Dunville R, Ocfemia CB, Salomon JA, Francke JA, Bulteel AJ, Wang LY, Hsu KK, DiNenno EA, **Walensky RP**, Parker RA, Freedberg KA, Ciaranello AL. The optimal age for screening adolescents and young adults without identified risk factors for HIV. *J Adolescent Health*. 2018; 62(1):22-28.
221. Dunning L, Francke JA, Mallampati D, MacLean RL, Penazzato M, Hou T, Myer L, Abrams EJ, **Walensky RP**, Leroy V, Freedberg KA, Ciaranello AL. The value of confirmatory testing in early infant HIV diagnosis (EID) programmes in South Africa: A cost-effectiveness analysis. *PLoS Med*. 2017; 14(11):e1002446.
222. Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, **Walensky RP**, Freedberg KA. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. *J Int AIDS Society*. 2018; 21(3):e25085.
223. Hyle EP, Mayosi BM, Middelkoop K, Martey EB, **Walensky RP**, Bekker LG, Triant VA. The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: a systematic review. *BMC Public Health*. 2017;17(1): 954.

224. Neilan AM, Cohn JE, Lemaire JF, Sacks E, Alban R, Freedberg KA, **Walensky RP**, Ciaranello AL. HIV testing after a first positive rapid diagnostic test: A role of nucleic acid testing? *OFID*. 2018; 5(8):ofy170.
225. Luz PM, Osher B, Grinstztejn B, Maclean RL, Losina EL, Stern ME, Struchiner CJ, Parker RA, Freedberg KA, Mesquita F, **Walensky RP**, Veloso VG, Paltiel AD. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. *J Int AIDS Society*. 2018; 21(3):e25096.
226. Mallampati D, MacLean RL, Shapiro R, Dabis F, Engelsmann B, Freedberg KA, Leroy V, Lockman S, **Walensky RP**, Rollins N, Ciaranello AC. Optimal breastfeeding durations for HIV-exposed infants: the impact of maternal ART use, infant mortality, and replacement feeding risk. *J Int AIDS Society*. 2018; 21(4):e25107.
227. Freedberg KA, Kumarasamy N, Borre ED, Ross EL, Mayer KH, Losina EL, Swaminathan S, Flanigan T, **Walensky RP**. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India. *AIDS Res Hum Retroviruses*. 2018; 34(6):486-497.
228. **Walensky RP**, Kim Y, Chang Y, Porneala BC, Bristol MN, Armstrong K, Campbell EG. The impact of active mentorship: Results from a survey of faculty in the Department of Medicine at Massachusetts General Hospital. *BMC Med Ed*. 2018; 18(1):108.
229. Blumenthal KG, Lu L, Zhang Y, Li Y, **Walensky RP**, Choi HK. Risk of methicillin-resistant *Staphylococcus aureus* and *Clostridium difficile* in patients with a documented penicillin allergy: A population-based matched cohort study. *BMJ*. 2018; 361:k2400.
230. O'Laughlin KN, He W, Greenwald KE, Kasozi J, Chang Y, Mulogo E, Faustin ZM, Njogu P, **Walensky RP**, Bassett IV. Feasibility and acceptability of home-based HIV testing among refugees: A pilot study in Nakivale Refugee Settlement in southwestern Uganda. *BMC Infectious Diseases*. 2018; 18(1):332.
231. Reddy KP, Gupta-Wright A, Fielding KL, Costantini S, Zheng A, Corbett EL, Yu L, van Oosterhout JJ, Resch SC, Wilson DP, Horsburgh CR, Wood R, Alufandika-Moyo M, Peters JA, Freedberg KA, Lawn SD, **Walensky RP**. Cost-effectiveness of urine-based tuberculosis testing in hospitalised patients with HIV in Africa. *Lancet Global Health*. 2019; 7(2):e200-e208.
232. Hyle EP, Fields NF, Fiebelkorn AP, Walker AT, Gastanaduy P, Rao SR, Ryan ET, LaRocque RC, **Walensky RP**. The clinical impact and cost-effectiveness of Measles-Mumps-Rubella vaccination to prevent Measles importations among international travelers from the United States. *Clin Infect Dis*. 2019; 69(2):306-315.
233. Costantini S, **Walensky RP**. The cost of drugs in infectious diseases: branded, generics, and why we should care. *J Infect Dis*. 2020;221(5).
234. Simpkin AL, Chang Y, Yu L, Campbell EG, Armstrong K, **Walensky RP**. Assessment of job satisfaction and feeling valued in academic medicine. *JAMA Int Med*. 2019; 179(7):992-994.

235. Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, **Walensky RP**. Risks and benefits of dolutegravir- and efavirenz-based strategies for South African women with HIV of childbearing potential: a modeling study. *Ann Intern Med*. 2019; 170(9):614-625.
236. Hyle EP, Bekker LG, Martey EB, Huang M, Xu A, Parker RA, **Walensky RP**, Middelkoop K. Cardiovascular risk factors among ART-experienced people with HIV in South Africa. *J Int AIDS Soc*. 2019; 22(4):e25274.
237. Blumenthal KG, Lu N, Zhang Y, **Walensky RP**, Choi HK. Recorded penicillin allergy and risk of mortality: A population-based matched cohort study. *J Gen Intern Med*. 2019; 34(9):1685-1687.
238. Kazemian P, Costantini S, Kumarasamy N, Paltiel AD, Mayer KH, Chandhiok N, **Walensky RP**, Freedberg KA. The cost-effectiveness of HIV pre-exposure prophylaxis and HIV testing strategies in high-risk groups in India. *Clin Infect Dis*. 2020; 70(4):633-642.
239. Bassett IV, Huang M, Cloete C, Candy S, Giddy J, Frank Simone, Freedberg KA, Losina E, **Walensky RP**, Parker RA. Using national laboratory data to assess cumulative frequency of linkage after transfer to community-based HIV clinics in South Africa. *J Int AIDS Soc*. 2019; 22(6):e25326.
240. Kazemian P, Wexler DJ, Fields NF, Parker RA, Zheng A, **Walensky RP**. Development and validation of PREDICT-DM: A new microsimulation model to project and evaluate complications and treatments of type 2 diabetes mellitus. *Diabetes Tech and Therap*. 2019; 21(6):344-355.
241. **Walensky RP**, Paltiel AD. Straight A's: New USPSTF guidelines for HIV screening and PrEP. *JAMA Network Open*. 2019; 2(6):e195042.
242. Hyle EP, Scott JA, Sax PE, Millham LRI, Dugdale CM, Weinstein MC, Freedberg KA, **Walensky RP**. Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States. *Clin Infect Dis*. 2020; 70(7):1353-1363.
243. Kazemian P, Shebl FM, McCann N, **Walensky RP**, Wexler DJ. Evaluation of the cascade of diabetes care in the United States, 2005-2016, *JAMA Intern Med*. 2019; 179(10):1376-1385.
244. Desmonde S, Frank SC, Coovadia A, Dahourou DL, Hou T, Abrams EJ, Amorissani-Folquet M, **Walensky RP**, Strehlau R, Penazzato M, Freedberg KA, Kuhn L, Leroy V, Ciaranello AL. Cost-effectiveness of preemptive switching to efavirenz-based antiretroviral therapy for children with HIV. *Open Forum Infect Dis*. 2019; 6(7):ofz276.
245. Ouattara EN, MacLean RL, Danel C, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholie SP, **Walensky RP**, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: a model based analysis. *PLoS One*. 2019; 14(6):e0219068.
246. **Walensky RP**, Paltiel AD. PrEP school: A field manual for the battle over HIV prevention drug pricing. *Health Affairs Blog*. 2019; 10.1377/hblog20190826.11005.

247. Wallace ZS, Harkness T, Fu X, Stone JH, Choi HK, **Walensky RP**. Treatment delays associated with prior authorization for infusible medications: a cohort study. *Arthritis Care and Research*. 2019; 72(11):1543-1549.
248. Blumenthal KG, Oreskovic NM, Fu X, Shebl FM, Mancini CM, Maniates JM, **Walensky RP**. High-cost high-need patients: the prevalence and impact of penicillin allergy. *Am J Manag Care*. 2020; 26(4):154-6.
249. Hyle EP, Gastanaduy P, Ban Fiebelkorn AP, Hagmann SHF, Walker A, **Walensky RP**, Ryan ET, LaRocque RC. Clinical practices for Measles-Mumps-Rubella vaccination among US pediatric international travelers. *JAMA Peds*. 2020; 174(2):e194515.
250. Millham LRI, Scott JA, Sax PE, Shebl FM, Reddy KP, Losina E, **Walensky RP**, Freedberg KA. Clinical and economic impact of ibalizumab for people with multidrug-resistant HIV in the United States. *JAIDS*. 2020; 83(2):148-156.
251. Goldstein RH, **Walensky RP**. Where were the women: gender parity in clinical trials. *New Engl J of Med*. 2019; 381(26):2491-2493.
252. Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugenyi PN, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Sise T, Fletcher CV, Gandhi M, **Walensky R**, Mansfield B, Mugerwa H, Ndege BW, Kadam D, Fontain SN, Nakibuuka L, Nassolo H, Anthony P, Kulkarni V, Nsubuga M, van Wyk J, Rooney J, van Delft Y, Leavitt R, Luk R, Benns A, Hovind L, Shahkolahi A and Team A. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. *The Lancet HIV*. 2019;6(9):e588-e600. 10.1016/S2352-3018(19)30146-8.
253. Reddy KP, Horsburgh CR, Wood R, Fields NF, Girouard MP, Costantini S, Hou T, Freedberg KA, **Walensky RP**. Shortened tuberculosis treatment for people with HIV in South Africa: a model-based evaluation and cost-effectiveness analysis. *Ann Am Thoracic Society*. 2019; 17(2):202-211.
254. Dugdale CM, Phillips TK, Myer L, Hyle EP, Brittain K, Freedberg KA, Cunnama L, **Walensky RP**, Zerbe A, Weinstein MC, Abrams EJ, Ciaranello AL and the MCH-ART Trial Team. Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal and child health services in South Africa. *PLoS One*. 2019; 14(11):e0225104.
255. Frank SC, Cohn J, Dunning L, Sacks E, **Walensky RP**, Mukherjee S, Dugdale CM, Turunga E, Freedberg KA and Ciaranello AL. Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. *Lancet HIV*. Mar 2019;6(3):e182-e190. 10.1016/s2352-3018(18)30328-x.
256. Mohareb AM, **Walensky RP**, Hyle EP. Correcting the contradictions: Immigration policy and HIV. *Health Affairs Blog*. 2019; 10.1377/hblog20191108.169361.

257. McCann NC, Horn TH, Hyle EP, **Walensky RP**. Antiretroviral therapy costs in the United States, 2012-2018. *JAMA Internal Medicine*. 2020; 180(4):601-603.
258. **Walensky RP**, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative pricing of branded tenofovir alafenamide/emtricitabine relative to generic tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: a cost-effectiveness analysis. *Annals Internal Medicine*. 2020; 172(9):583-590.
259. Tseng CW, Dudley RA, Chen R, **Walensky RP**. Medicare Part D and cost-sharing for antiretroviral therapy and preexposure prophylaxis. *JAMA Open Network*. 2020; 3(4):e202739.
260. Wallace ZS, Harkness T, Blumenthal KG, Choi HK, Stone JH, **Walensky RP**. Increasing operational capacity and reducing costs of rituximab administration: a costing analysis. *ACR Open Rheumatology*. 2020; 2(5):261-268.
261. McCann NC, Cohn J, Flanagan C, Sacks E, Mukherjee S, **Walensky RP**, Adetunji O, Maeka KK, Panella C, Chadmbuka A, Mafaune H, Odhiambo CH, Freedberg KA, Ciaranello AL. Strengthening existing laboratory-based systems versus investing in point-of-care assays for early infant diagnosis of HIV: a model-based cost-effectiveness analysis. *J Acquir Immune Defic Syndr*. 2020; Suppl 1(1):S12-S21.
262. Reddy KP, Bulteel AJB, Levy DE, Torola P, Hyle EP, Hou T, Osher B, Yu L, Shebl FM, Paltiel AD, Freedberg KA, Weinstein MC, Rigotti NA, **Walensky RP**. A novel microsimulation model of tobacco use behaviors and outcomes: calibration and validation in a US population. *BMJ Open*. 2020; 10(5):e032579.
263. **Walensky RP**, del Rio C. From mitigation to containment of the COVID-19 pandemic: putting the SARS-CoV-2 genie back in the bottle. *JAMA*. 2020; 323(19):1889-1890.
264. Mancini CM, Fu X, Zhang Y, Kuper K, Schulz LT, Bhowmick T, Postelnick M, Lee F, **Walensky RP**, Blumenthal KG. Penicillin allergy evaluation access: a national survey. *Clin Infect Dis*. Dec 31 2020;71(11):2972-2975. 10.1093/cid/ciaa567
265. Marcus JL, Paltiel AD and **Walensky RP**. Has pre-exposure prophylaxis made a difference at a population level? Jury is still out. *Clin Infect Dis*. Dec 15 2020;71(12):3152-3153. 10.1093/cid/ciz1236.
266. Blumenthal KG, Kuper K, Schulz LT, Bhowmick T, Postelnick M, Lee F, **Walensky RP**. Association between penicillin allergy documentation and antibiotic use. *JAMA Intern Med*. 2020;180(8):1120-1122.
267. Soeteman DI, Resch SC, Jalal H, Dugdale CM, Penazzato M, Weinstein MC, Phillips A, Hou T, Abrams EJ, Dunning L, Newell ML, Pei PP, Freedberg KA, **Walensky RP**, Ciaranello AL. Developing and validating metamodels of a microsimulation model of infant HIV testing and screening strategies used in a decision support tool for health policy makers. *MDM Policy Pract*. 2020; 5(1):2381468320932894.

268. Kazemian P, Costantini S, Neilan AM, Resch SC, **Walensky RP**, Weinstein MC, Freedberg KA. A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. *J Biomedical Informatics*. 2020; 107:103475.
269. **Walensky RP**, McQuillen DP, Shahbazi S, Goodson JD. Where is the ID in COVID-19? *Ann Intern Med*. 2020; 173(7):587-589.
270. Neilan AM, Bulteel AJB, Hosek GH, Foote JHA, Freedberg KA, Landovitz FJ, **Walensky RP**, Resch SC, Kazemian P, Paltiel AD, Weinstein MC, Wilson CM, Ciaranello AL. Cost-effectiveness of frequent HIV screening among high-risk young men who have sex with men in the United States. *Clin Infect Dis*. 2020; Oct 17 2017;216(7):798-807. 10.1093/infdis/jix349.
271. Dugdale CM, **Walensky RP**. The filtration efficiency, effectiveness, and availability of N95 facemasks for COVID-19 prevention. *JAMA Intern Med*. Aug 11 2020;10.1001/jamainternmed.2020.4218.
272. Paltiel AD, Zheng A, **Walensky RP**. COVID-19 screening strategies that permit the safe re-opening of college campuses. *JAMA Netw Open*. Jul 1 2020;3(7):e2016818. 10.1001/jamanetworkopen.2020.16818.
273. Brown TS, **Walensky**. Sero-surveillance and the COVID-19 epidemic in the United States: undetected, uncertain, and the out of control. *JAMA*. 2020; 324(8):749-751.
274. Reddy YNV, **Walensky RP**, Mendu ML, Green N, Reddy KP. Estimating the capacity to deliver continuous kidney replacement therapy during the COVID-19 pandemic in the United States. *Am J Kidney Dis*. 2020; 76(5):696-709.e1.
275. Ard KL, **Walensky RP**. Payments for PrEP in the United States: too much for too few? *Ann Int Med*. 2020; 173(10):844-845.
276. Dugdale CM, Turbett SE, McCluskey SM, Zachary KC, Shenoy ES, Ciaranello AL, **Walensky RP**, Rosenberg ES, Anahtar MN, Hooper DC, and Hyle EP. Outcomes from an infectious disease physician-guided evaluation of hospitalized persons under investigation for COVID-19 at a large US academic medical center. *Infect Control Hosp Epidemiol*. 2020;10.1017/ice.2020.434
277. Sacks CA, Dougan ML, McCoy T, Zheng A, Buonomo G, North CM, Metlay JP, **Walensky RP**. The association of symptoms and COVID-19 test results among healthcare workers. *Ann Surg*. 2020; 272(6):e329-e332.
278. Yamey G, **Walensky RP**. Covid-19: re-opening universities is high risk. *BMJ*. 2020; 370:m3365
279. Beyrer C, Adimora AA, Hodder SL, Hopkins E, Millett G, Mon SHH, Sullivan PS, **Walensky RP**, Pozniak A, Warren M, Richman B, Copeland R and Mayer KH. Call to action: how can the US Ending the HIV Epidemic initiative succeed? *Lancet*. Mar 20 2021;397(10279):1151-1156.
280. Paltiel AD, **Walensky RP**. Screening to prevent SARS-CoV2 outbreaks: saliva-based antigen testing is better than the PCR swab. *Health Affairs Blog*. 2020; 10.1377/hblog20200909.430047.

281. Kates J, Dawson L, Horn TH, Killelea A, McCann N, Crowley JS, **Walensky RP**. Insurance coverage and financing landscape of HIV treatment and prevention in the United States. *Lancet*. Mar 20 2021;397(10279):1127-1138. 10.1016/s0140-6736(21)00397-4
282. Goldstein RH, **Walensky RP**. The challenges ahead with monoclonal antibodies: from authorization to access. *JAMA*. 2020; 324(21):2151-2152.
283. O’Laughlin KN, Xu A, Greenwald KE, Kasozi J, Parker RA, Bustamante N, Parmar P, Faustin ZM, **Walensky RP**, Bassett IV. A cohort study to assess a communication intervention to improve linkage to HIV care in Nakivale Refugee Settlement, Uganda. *Global Public Health*. Jul 16 2018;18(1):332. 10.1186/s12879-018-3238-y.
284. Alwan NA, Burgess RA, Ashworth S, Beale R, Bhadelia N, Bogaert B, Dowd J, Eckerle I, Goldman LR, Greenhalgh T, Gurdasani D, Hamdy A, Hanage WP, Hodcroft EB, Hyde Z, Kellam P, Kelly-Irving M, Krammer F, Lipsitch M, McNally A, McKee M, Nouri A, Pimenta D, Priesemann V, Rutter H, Silver J, Sridhar D, Swanton C, **Walensky RP**, Yamey G, Ziauddeen H. Scientific consensus on the COVID-19 pandemic: we need to act now. *Lancet*. 2020; 396(10260):e71-e72.
285. Reddy KP, Denkinger CM, Broger T, McCann NC, Gupta-Wright A, Kerkhoff AD, Pei PP, Shebl FM, Fielding KL, Nicol MP, Horsburgh CR, Meintjes G, Freedberg KA, Wood R, **Walensky RP**. Cost-effectiveness of a novel lipoarabinomannan test for tuberculosis in patients with HIV. *Clin Infect Dis*. Nov 17 2020;10.1093/cid/ciaa1698.
286. Mohareb AM, Letourneau AR, Sanchez SM, **Walensky RP**, Hyle EP. Addressing antibiotic overuse in the outpatient setting: lessons from behavioral economics. *Mayo Clin Proc*. Mar 2021;96(3):537-542. 10.1016/j.mayocp.2020.10.033
287. Neilan AM, Bangs AC, Hudgens M, Patel K, Agwu AL, Bassett IV, Gaur AH, Hyle EP, Crespi CM, Horvath KJ, Dugdale CM, Powers KA, Rendina HJ, Weinstein MC, **Walensky RP**, Freedberg KA and Ciaranello AL. Modeling adherence interventions among youth with HIV in the United States: clinical and economic projections. *AIDS Behav*. Feb 6 2021;10.1007/s10461-021-03169-0.
288. Dugdale CM*, Anahtar MN*, Chiosi JJ, Lazarus JE, McCluskey SM, Ciaranello AL, Gogakos T, Little BP, Branda JA, Shenoy ES, **Walensky RP**, Zachary KC, Hooper DC, Turbett SE**, and Hyle EP**. Clinical, laboratory, and radiologic characteristics of patients with initial false-negative SARS-CoV-2 nucleic acid test results. *Open Forum Infectious Diseases*. 2021 Jan; 8(1):ofaa559. PMID: 34164560.
289. Dugdale CM, Rubins DM, Lee H, McCluskey SM, Ryan ET, Kotton CN, Hurtado RM, Ciaranello AL, Barshak MB, McEvoy DS, Nelson SB, Basgoz N, Lazarus JE, Ivers LC, Reedy JL, Hysell KM, Lemieux JE, Heller HM, Dutta S, Albin JS, Brown TS, Miller AL, Calderwood SB, **Walensky RP**, Zachary KC, Hooper DC, Hyle EP and Shenoy ES. COVID-19 diagnostic clinical decision support: a pre-post implementation study of CORAL (COvid Risk cALculator). *Clin Infect Dis*. Feb 10 2021;10.1093/cid/ciab111.

290. Paltiel AD, Schwartz JL, Zheng A, **Walensky RP**. Clinical outcomes of a COVID-19 vaccine: implementation over efficacy. *Health Affairs Blog*. 2020; 10.1377/hlthaff.2020.02054.
291. **Walensky RP**, Walke HT and Fauci AS. SARS-CoV-2 variants of concern in the United States - challenges and opportunities. *JAMA*. Mar 16 2021;325(11):1037-1038. 10.1001/jama.2021.2294.
292. Faust JS, Krumholz HM, Du C, Dickerson Mayes K, Lin Z, Gilman C, **Walensky R**. All-cause excess mortality and COVID-19 related mortality among US adults ages 25-44 years, March-July 2020. *JAMA*. Feb 23 2021;325(8):785-787. 10.1001/jama.2020.24243
293. Christie A, Mbaeyi SA and **Walensky RP**. CDC interim recommendations for fully vaccinated people: an important first step. *JAMA*. Apr 20 2021;325(15):1501-1502. 10.1001/jama.2021.4367.
294. Reddy KP, Schwamm E, Kalkhoran S, Noubary F, **Walensky RP** and Rigotti NA. Respiratory symptom incidence among people using electronic cigarettes, combustible tobacco, or both. *Am J Respir Crit Care Med*. Apr 15 2021;10.1164/rccm.202012-4441LE.
295. Hyle EP, Martey EB, Bekker L, Xu A, Parker RA, **Walensky RP**, Middelkoop K. Diet, physical activity, and obesity among ART-experienced people with HIV in South Africa. *J Int AIDS Soc*. April 2019; 22(4):e25274. PMID: 30990252.
296. Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, **Walensky RP**. Cost-effectiveness of long-acting injectable HIV pre-exposure prophylaxis in the United States. *Ann Intern Med*. 2022 Feb 1. doi: 10.7326/M21-1548. Epub ahead of print. PMID: 35099992.
297. Paltiel AD, Zheng A, **Walensky RP**. Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. *JAMA Netw Open*. 2020 Jul 1; 3(7): e2016818. doi: 10.1001/jamanetworkopen.2020.16818. PMID: 32735339; PMCID: PMC7395236.
298. Rubin EJ, Baden LR, **Walensky RP**, Morrissey S. Audio Interview: Covid-19 Vaccines and Pregnancy - A Conversation with CDC Director Rochelle Walensky. *N Engl J Med*. 2021 Apr 22; 384(16):e73. doi: 10.1056/NEJMe2106836. PMID: 33882211.
299. Brooks JT, Marks P, Goldstein RH, **Walensky RP**. Intradermal Vaccination for Monkeypox — Benefits for Individual and Public Health. *N Engl J Med*. 2022, Sept 29. doi: 10.1056/NEJMp2211311
300. Becerra X, Palm A, Haffajee RL, Contreras K, Barkoff A, O'Connell D, Valdez RO, **Walensky RP**, Brooks-LaSure C, Califf RM, Johnson C, Tso R, Tabak LA, Levine RL, Tripathi M, Delphin-Rittmon M, Murthy VH. Addressing The Nation's Behavioral Health Crisis: An HHS Roadmap to Integrate Behavioral Health. *Health Affairs Forefront*. 2022, Dec 2. doi: 10.1377/forefront.20221130.118858.
301. **Walensky RP**. Partnerships, Collaborations, and Investments Integral to CDC's International Response to COVID-19. *Emerging Infectious Diseases*. 2022; 28(13):1-3. doi:10.3201/eid2813.221751.

302. Berger SA, **Walensky RP**. Reflecting on ACP's Position Paper for Public Health: A View from the CDC Lens. *Ann Intern Med*. In press.
303. Wallender E, Peacock G, Wharton M, **Walensky RP**. Uninsured and not immune: closing the vaccine coverage gap for adults. *N Engl J Med*. In press.
304. **Walensky RP**. Gratitude for Public Health: COVID-19 and Beyond. *Public Health Reports*. 2023;138(4):565-566. doi:10.1177/00333549231169956.

Non-peer reviewed scientific or medical publications/materials in print or other media

Clinical Contributions (peer-reviewed)

1. **Walensky RP**, Venbrux AC, Prescott CA, Osterman FA Jr. Pseudomyxoma peritonei: pictorial essay. *Am J Roentgenol* 1996; 167:471-474.
2. **Walensky RP**, Hellmann DB. Case of the month. *Am J Med* 1998; 105:544-545.
3. **Walensky RP**, Goldberg J, Daily J. Anaphylaxis after rechallenge with abacavir. *AIDS* 1999; 13:999-1000.
4. Ciaranello A, Olans R, **Walensky RP**. Vesiculopapular rash. *Clin Infect Dis* 2006; 43:1308, 1368-9.
5. Cha JJ, Furie K, Kay J, **Walensky RP**, Mullins ME, Hedley-White ET. Clinical Pathologic Conference: A 24-year-old woman with systemic lupus erythematosus and recent seizures and right arm weakness. *N Eng J Med* 2006; 355:2678-2689.
6. Asmal M, Factor RE, **Walensky RP**. Photo quiz. An HIV-infected man with an upset stomach. *Clin Infect Dis* 2008; 47: 935-6; 979-80.
7. **Walensky RP**. A piece of my mind. Disclosure. *JAMA*. 2010; 303(17):1676-7.

Other Contributions (not peer-reviewed)

1. **Walensky RP**. An added value of rapid testing: improved quality of care, *AIDS Clinical Care*. October 26, 2005.
2. **Walensky RP**. Missed opportunities of earlier HIV diagnosis. *AIDS Clinical Care*. December 18, 2006.
3. **Walensky RP**. APTIMA assay approved for HIV drug testing. *AIDS Clin Care*. Dec 2006;18(12):109-10.
4. **Walensky RP**. Do HIV testing rates improve when written consent is no longer required? *AIDS Clinical Care*. May 26, 2007.

5. **Walensky RP.** Survival benefits of retention in care. *AIDS Clinical Care*. June 4, 2007.
6. **Walensky RP.** Limitations of rapid testing. *AIDS Clinical Care*. July 16, 2007.
7. **Walensky RP.** Implementing routine HIV testing: the role of state law. *AIDS Clinical Care*. November 5, 2007.
8. **Walensky RP.** ART as a prevention intervention. *AIDS Clinical Care*. June 16, 2008.
9. Linas BP and **Walensky RP.** Cost-effectiveness of monitoring and treatment strategies in resource-limited settings. *AIDS Clinical Care*. October 20, 2008.
10. **Walensky RP.** Too few HIV-infected patients are receiving care. *AIDS Clinical Care*. March 30, 2009.
11. **Walensky RP.** Loss to follow-up worsen outcomes for HIV patients, even if they return to care. *AIDS Clinical Care*. August 3, 2009.
12. **Walensky RP.** Finding the time. *Group on Women in Medicine and Science (GWIMS) Newsletter*, AAMC. July 2010.
13. **Walensky RP.** Can we get even more bang from TNT? *AIDS Clinical Care*. August 23, 2010
14. **Walensky RP.** More support for expanded HIV screening and ART in the US. January, 2011.
15. Case #14003: An elderly man with hematuria, dysuria, nausea and vomiting. [Internet]. Partners Infectious Disease Images. Available from: <http://www.idimages.org/idreview/case/caseid=498>.
16. Case #14004: A man with headache, cough, chills, and a rash. [Internet]. Partners Infectious Disease Images. Available from: <http://www.idimages.org/idreview/case/caseid=14004>.
17. Case #510: A young woman with pain and an enlarging 'lump' on her flank. [Internet]. Partners Infectious Disease Images. Available from: <http://www.idimages.org/idreview/case/?CaseID=510>.

Book Chapters

1. Beck E, **Walensky RP.** "The Outcome and Impact of Ten Years of HAART" In *A Decade of HAART: Historical Perspectives and Future Directions*. Editors: Bartlett JG, Lange JMA, Whiteside A, Zuniga JM, Ghaziani A.

Congressional Testimonies

1. U.S. House. Committee on Oversight and Reform. *HIV Prevention Drug: Billions in Corporate Profits after Millions in Taxpayer Investments*. (HHRG-116-GO00; May 2019). Testimony of Rochelle P. Walensky.
2. U.S. House. Subcommittee on Oversight and Investigations (Committee on Energy and Commerce). *Leading the Way Forward: Biden Administration Actions to Increase COVID-19 Vaccinations*. (HHRG-117-IF02; Mar 2021). Witness Statement of Rochelle P. Walensky.
3. U.S. Senate. Committee on Health, Education, Labor, & Pensions. *Examining Our COVID-19 Response: An Update from Federal Officials*. (Mar 2021). Testimony of Rochelle P. Walensky.
4. U.S. House. Select Subcommittee on the Coronavirus Crisis. *Reaching the Light at the End of the Tunnel: A Science-Driven Approach to Swiftly and Safely Ending the Pandemic*. (HHRG-117-VC00; Apr 2021). Testimony of Rochelle P. Walensky.
5. U.S. House. Subcommittee on Labor, Health and Human Services, Education, and Related Agencies (Committee on Appropriations). *FY 2022 Budget Request for the Centers for Disease Control and Prevention*. (HHRG-117-AP07; May 2021). Testimony of Rochelle P. Walensky.
6. U.S. Senate. Committee on Appropriations. *Review of the FY2022 Budget Blueprint for the Centers for Disease Control and Prevention*. (May 2021). Testimony of Rochelle P. Walensky.
7. U.S. Senate. Committee on Health, Education, Labor, & Pensions. *An Update from Federal Officials on Efforts to Combat COVID-19*. (May 2021). Testimony of Rochelle P. Walensky.
8. U.S. Senate. Committee on Health, Education, Labor, & Pensions. *An Update from Federal Officials on Efforts to Combat COVID-19*. (May 2021). Testimony of Rochelle P. Walensky.
9. U.S. Senate. Committee on Health, Education, Labor, & Pensions. *The Path Forward: A Federal Perspective on the COVID-19 Response*. (July 2021). Testimony of Rochelle P. Walensky.
10. U.S. Senate. Committee on Health, Education, Labor, & Pensions. *Next Steps: The Road Ahead for the COVID-19 Response*. (Nov 2021). Testimony of Rochelle P. Walensky.
11. U.S. Senate. Committee on Health, Education, Labor, & Pensions. *Addressing New Variants: A Federal Perspective on the COVID-19 Response*. (Jan 2022). Testimony of Rochelle P. Walensky.
12. U.S. Senate. Subcommittee on Labor, Health and Human Services, Education and Related Agencies. *Review of the FY2022 Budget Blueprint for the Centers for Disease Control and Prevention*. (May 2022). Testimony of Rochelle P. Walensky.
13. U.S. House. Subcommittee on Labor, Health and Human Services, Education, and Related Agencies. *FY 2022 Budget Request for the Centers for Disease Control and Prevention*. (May 2022). Testimony of Rochelle P. Walensky.
14. U.S. Senate. Committee on Health, Education, Labor, & Pensions. *An Update on the Ongoing Federal Response to COVID-19: Current Status and Future Planning*. (June 2022). Testimony of Rochelle P. Walensky.
15. U.S. House. Joint Oversight and Investigations Subcommittee and Health Subcommittee Hearing. *The Federal Response to COVID-19*. (Feb 2023). Testimony of Rochelle P. Walensky.
16. U.S. House. Subcommittee on Labor, Health and Human Services, Education, and Related Agencies. *Fiscal Year 2024 Request for the Centers for Disease Control and Prevention, Administration for Strategic Preparedness and Response, and National Institute of Health*. (April 2023). Testimony of Rochelle P. Walensky.

17. U.S. Senate. Committee on Health, Education, Labor, & Pensions. *Preparing for the Next Public Health Emergency: Reauthorizing the Pandemic and All-Hazards Preparedness Act*. (May 2023). Testimony of Rochelle P. Walensky.
18. U.S. House Energy and Commerce Subcommittee on Health. *Preparing for and Responding to Future Public Health Security Threats*. (May 2023). Testimony of Rochelle P. Walensky.